Diagnoses of HIV Infection in the United States and Dependent Areas, 2020: Tables

All Tables
Table 1a. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2016–2020—United States
2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Gender
Male 31,332 30,461 29,730 28,948 24,269
Female 7,512 7,300 7,084 6,917 5,439
Transgender woman/girlb 675 612 627 652 638
Transgender man/boyb 22 33 48 45 40
Additional gender identityc 11 15 15 23 17
Age at diagnosis (yr)
<13 130 0.2 105 0.2 87 0.2 57 0.1 57 0.1
13–14 26 0.3 25 0.3 20 0.2 21 0.3 12 0.1
15–19 1,715 8.1 1,786 8.5 1,719 8.2 1,648 7.8 1,248 6.0
20–24 6,915 30.9 6,466 29.3 6,109 28.0 5,969 27.6 4,822 22.3
25–29 7,947 34.6 7,723 33.1 7,711 32.7 7,402 31.4 6,061 26.1
30–34 5,641 25.8 5,672 25.8 5,673 25.6 5,673 25.3 5,197 22.8
35–39 4,210 20.3 4,260 20.1 4,209 19.5 4,140 19.0 3,409 15.6
40–44 3,245 16.5 2,980 15.2 2,971 15.1 2,974 14.9 2,515 12.4
45–49 3,046 14.6 2,930 14.0 2,780 13.4 2,575 12.6 2,072 10.4
50–54 2,856 13.1 2,637 12.4 2,455 11.8 2,312 11.3 1,857 9.1
55–59 1,882 8.6 1,872 8.5 1,843 8.4 1,832 8.4 1,575 7.3
60–64 1,080 5.6 1,083 5.4 1,046 5.2 1,107 5.4 885 4.3
≥65 859 1.7 882 1.7 881 1.7 875 1.6 693 1.2
Race/ethnicity
American Indian/Alaska Native 216 9.1 200 8.3 173 7.2 205 8.5 201 8.3
Asian 931 5.2 930 5.1 868 4.6 739 3.9 637 3.3
Black/African American 16,799 41.7 16,279 40.1 15,786 38.6 15,503 37.6 12,856 31.0
Hispanic/Latinod 10,101 17.6 9,941 17.0 9,956 16.7 9,896 16.4 8,008 13.1
Native Hawaiian/other Pacific Islander 38 6.7 51 8.8 61 10.3 66 10.9 66 10.8
White 9,885 5.0 9,643 4.9 9,448 4.8 9,070 4.6 7,843 4.0
Multiracial 1,582 23.2 1,377 19.7 1,212 16.9 1,106 15.0 792 10.5
Transmission categorye
Male sex at birth (≥13 yrs at diagnosis)f
     Male-to-male sexual contact 25,948 25,346 24,545 23,975 20,572
     Injection drug use 1,189 1,292 1,407 1,381 1,178
Male-to-male sexual contact and injection drug use 1,539 1,470 1,465 1,524 1,105
     Heterosexual contactg 3,251 2,902 2,877 2,669 2,012
     Perinatalh 10 14 16 20 9
     Otheri 15 17 21 19 20
     Subtotal 31,952 24.2 31,041 23.3 30,331 22.6 29,589 21.9 24,897 18.3
Female sex at birth (≥13 yrs at diagnosis)f
  Injection drug use 1,034 1,086 1,105 1,154 855
     Heterosexual contactg 6,380 6,131 5,928 5,730 4,536
     Perinatalh 48 51 46 47 51
     Otheri 8 7 7 7 7
     Subtotal 7,470 5.4 7,275 5.2 7,086 5.1 6,939 4.9 5,449 3.8
Child (<13 yrs at diagnosis)
     Perinatal 107 88 68 46 44
     Otheri 23 17 19 11 13
     Subtotal 130 0.2 105 0.2 87 0.2 57 0.1 57 0.1
Region of residencej
Northeast 6,211 11.1 5,987 10.7 5,565 9.9 5,312 9.5 4,271 7.6
Midwest 5,172 7.6 5,115 7.5 4,940 7.2 4,748 6.9 4,127 6.0
South 20,274 16.6 19,725 16.0 19,412 15.6 19,181 15.3 15,689 12.4
West 7,895 10.3 7,594 9.8 7,587 9.7 7,344 9.4 6,316 8.0
Total 39,552 12.2 38,421 11.8 37,504 11.5 36,585 11.1 30,403 9.2

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

aRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
b“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
dHispanic/Latino persons can be of any race.
eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
fData include transgender and additional gender identity persons.
gSexual contact with a person known to have, or with a risk factor for, HIV infection.
hIndividuals were ≥13 years of age at time of diagnosis of HIV infection.
iOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
jData are based on residence at time of diagnosis of HIV infection.

Table 1b. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2016–2020—United States and 6 dependent areas
2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Gender
Male 31,774 30,825 30,098 29,277 24,515
Female 7,617 7,394 7,164 6,998 5,480
Transgender woman/girlb 678 614 629 654 640
Transgender man/boyb 22 33 49 45 40
Additional gender identityc 11 15 15 23 17
Age at diagnosis (yr)
<13 130 0.2 105 0.2 87 0.2 57 0.1 57 0.1
13–14 26 0.3 25 0.3 20 0.2 21 0.2 12 0.1
15–19 1,725 8.1 1,798 8.4 1,736 8.1 1,654 7.8 1,256 5.9
20–24 6,988 30.9 6,532 29.3 6,171 28.0 6,026 27.5 4,867 22.3
25–29 8,018 34.6 7,786 33.0 7,788 32.7 7,461 31.4 6,103 26.0
30–34 5,706 25.9 5,734 25.9 5,731 25.7 5,730 25.3 5,233 22.7
35–39 4,280 20.4 4,312 20.1 4,243 19.5 4,179 19.0 3,445 15.6
40–44 3,302 16.6 3,015 15.2 3,012 15.1 3,013 15.0 2,540 12.4
45–49 3,105 14.7 2,971 14.1 2,824 13.5 2,612 12.7 2,094 10.4
50–54 2,901 13.2 2,687 12.5 2,504 11.9 2,342 11.3 1,883 9.1
55–59 1,930 8.7 1,907 8.6 1,871 8.4 1,869 8.5 1,599 7.3
60–64 1,107 5.6 1,106 5.5 1,066 5.2 1,131 5.4 901 4.3
≥65 884 1.8 903 1.8 902 1.7 902 1.6 702 1.2
Race/ethnicity
American Indian/Alaska Native 216 200 173 205 201
Asian 932 933 872 746 637
Black/African American 16,805 16,283 15,794 15,508 12,859
Hispanic/Latinod 10,636 10,387 10,388 10,287 8,294
Native Hawaiian/other Pacific Islander 43 52 63 70 66
White 9,887 9,648 9,451 9,075 7,843
Multiracial 1,583 1,378 1,214 1,106 792
Transmission categorye
Male sex at birth (≥13 yrs at diagnosis)f
Male-to-male sexual contact 26,244 25,580 24,810 24,204 20,758
Injection drug use 1,225 1,326 1,431 1,406 1,198
Male-to-male sexual contact and injection drug use 1,551 1,483 1,477 1,536 1,109
 Heterosexual contactg 3,353 2,987 2,947 2,734 2,051
    Perinatalh 10 14 16 20 9
    Otheri 15 17 21 19 20
    Subtotal 32,397 24.2 31,407 23.3 30,701 22.6 29,920 21.9 25,145 18.3
Female sex at birth (≥13 yrs at diagnosis)f
     Injection drug use 1,046 1,095 1,107 1,160 857
     Heterosexual contactg 6,473 6,216 6,008 5,805 4,575
     Perinatalh 48 51 46 47 51
     Otheri 8 7 7 7 7
     Subtotal 7,575 5.4 7,369 5.2 7,167 5.1 7,020 4.9 5,490 3.8
Child (<13 yrs at diagnosis)
     Perinatal 107 88 68 46 44
     Otheri 23 17 19 11 13
     Subtotal 130 0.2 105 0.2 87 0.2 57 0.1 57 0.1
Region of residencej
Northeast 6,211 11.1 5,987 10.7 5,565 9.9 5,312 9.5 4,271 7.6
Midwest 5,172 7.6 5,115 7.5 4,940 7.2 4,748 6.9 4,127 6.0
South 20,274 16.6 19,725 16.0 19,412 15.6 19,181 15.3 15,689 12.4
West 7,895 10.3 7,594 9.8 7,587 9.7 7,344 9.4 6,316 8.0
U.S. dependent areas 550 14.4 460 12.4 451 12.6 412 11.5 289 8.1
Total 40,102 12.3 38,881 11.8 37,955 11.5 36,997 11.1 30,692 9.2

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

aRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.
b“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
dHispanic/Latino persons can be of any race.
eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
fData include transgender and additional gender identity persons.
gSexual contact with a person known to have, or with a risk factor for, HIV infection.
hIndividuals were ≥13 years of age at time of diagnosis of HIV infection.
iOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
jData are based on residence at time of diagnosis of HIV infection.

Table 2a. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID-19 Pandemic)—United States
American Indian/Alaska Native Asian Black/African American Hispanic/Latinoa Native Hawaiian/other Pacific Islander White Multiracial Total
No. Rateb No. Rateb No. Rateb No. Rateb No. Rateb No. Rateb No. Rateb No. Rateb
Gender
Male 149 532 9,558 6,885 48 6,471 626 24,269
Female 44 88 2,970 907 15 1,281 134 5,439
Transgender woman/girlc 8 16 309 202 3 72 28 638
Transgender man/boyc 0 0 11 10 0 15 4 40
Additional gender identityd 0 1 8 4 0 4 0 17
Age at diagnosis (yr)
<13 1 0.2 2 0.1 32 0.4 9 0.1 1 0.9 12 0.0 0 0.0 57 0.1
13–14 0 0.0 0 0.0 8 0.7 4 0.2 0 0.0 0 0.0 0 0.0 12 0.1
15–19 5 2.8 19 1.7 735 25.7 294 5.8 4 9.6 149 1.4 42 5.4 1,248 6.0
20–24 28 15.4 68 5.5 2,544 83.7 1,231 25.1 8 18.6 792 6.9 151 21.8 4,822 22.3
25–29 36 18.2 144 9.4 2,646 77.0 1,707 34.4 15 30.2 1,336 10.7 177 29.1 6,061 26.1
30–34 35 19.3 111 6.6 2,159 68.3 1,447 31.0 10 18.7 1,323 10.5 112 23.9 5,197 22.8
35–39 30 18.7 72 4.4 1,232 44.1 996 22.1 10 20.0 976 7.9 93 24.1 3,409 15.6
40–44 25 17.2 55 3.8 882 33.9 745 17.6 6 14.0 734 6.4 68 21.0 2,515 12.4
45–49 11 7.8 58 4.1 737 29.2 524 13.6 4 10.6 682 5.8 56 20.2 2,072 10.4
50–54 16 11.2 41 3.3 640 25.4 466 13.8 3 8.4 656 5.1 35 14.3 1,857 9.1
55–59 7 4.5 24 2.1 602 23.2 298 10.2 3 8.6 615 4.2 26 11.1 1,575 7.3
60–64 4 2.8 22 2.2 363 15.2 173 7.4 2 6.6 301 2.1 20 9.5 885 4.3
≥65 3 0.9 21 0.8 276 5.3 114 2.3 0 0.0 267 0.6 12 2.6 693 1.2
Transmission categorye
     Male sex at birth (≥13 yrs at diagnosis)f
Male-to-male sexual contact 126 491 8,062 6,176 42 5,126 550 20,572
Injection drug use 8 14 313 261 3 539 42 1,178
Male-to-male sexual contact and injection drug use 20 12 230 256 3 545 38 1,105
Heterosexual contactg 3 30 1,240 390 2 325 24 2,012
     Perinatalh 0 0 8 0 0 1 0 9
     Otheri 0 2 8 3 0 6 0 20
     Subtotal 157 16.0 549 7.1 9,859 60.9 7,086 29.4 50 19.9 6,542 7.8 654 26.8 24,897 18.3
    Female sex at birth (≥13 yrs at diagnosis)
Injection drug use 20 6 250 134 2 422 21 855
Heterosexual contactg 23 79 2,674 773 12 858 116 4,536
     Perinatalh 0 1 40 5 0 5 1 51
     Otheri 0 1 1 1 0 4 0 7
     Subtotal 43 4.2 86 1.0 2,965 16.4 913 3.8 15 6.0 1,289 1.5 138 5.3 5,449 3.8
     Child (<13 yrs at diagnosis)
     Perinatal 0 0 26 8 1 9 0 44
     Otheri 1 2 6 1 0 3 0 13
     Subtotal 1 0.2 2 0.1 32 0.4 9 0.1 1 0.9 12 0.0 0 0.0 57 0.1
Region of residencej
Northeast 7 5.4 93 2.4 1,721 27.2 1,340 16.0 4 17.7 972 2.7 134 13.2 4,271 7.6
Midwest 32 7.7 75 3.1 1,980 27.5 515 9.1 5 12.9 1,396 2.7 124 8.6 4,127 6.0
South 49 6.0 151 3.2 8,081 33.3 3,435 14.6 13 12.9 3,566 5.0 394 15.6 15,689 12.4
West 113 10.5 318 3.8 1,074 29.6 2,718 11.4 44 9.8 1,909 4.9 140 5.5 6,316 8.0
Total 201 8.3 637 3.3 12,856 31.0 8,008 13.1 66 10.8 7,843 4.0 792 10.5 30,403 9.2

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

aHispanic/Latino persons can be of any race.
bRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
c“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
dAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
fData presented include transgender and additional gender identity persons.
gSexual contact with a person known to have, or with a risk factor for, HIV infection.
hIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
iOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
jData are based on residence at time of diagnosis of HIV infection.

Table 2b. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID-19 Pandemic)—United States and 6 dependent areas
American Indian/Alaska Native Asian Black/African American Hispanic/Latinoa Native Hawaiian/other Pacific Islander White Multiracial Total
No. No. No. No. No. No. No. No.
Gender
Male 149 532 9,561 7,128 48 6,471 626 24,515
Female 44 88 2,970 948 15 1,281 134 5,480
Transgender woman/girlb 8 16 309 204 3 72 28 640
Transgender man/boyb 0 0 11 10 0 15 4 40
Additional gender identityc 0 1 8 4 0 4 0 17
Age at diagnosis (yr)
<13 1 2 32 9 1 12 0 57
13–14 0 0 8 4 0 0 0 12
15–19 5 19 737 300 4 149 42 1,256
20–24 28 68 2,544 1,276 8 792 151 4,867
25–29 36 144 2,646 1,749 15 1,336 177 6,103
30–34 35 111 2,160 1,482 10 1,323 112 5,233
35–39 30 72 1,232 1,032 10 976 93 3,445
40–44 25 55 882 770 6 734 68 2,540
45–49 11 58 737 546 4 682 56 2,094
50–54 16 41 640 492 3 656 35 1,883
55–59 7 24 602 322 3 615 26 1,599
60–64 4 22 363 189 2 301 20 901
≥65 3 21 276 123 0 267 12 702
Transmission categoryd
     Male sex at birth (≥13 yrs at diagnosis)e
Male-to-male sexual contact 126 491 8,064 6,359 42 5,126 550 20,758
Injection drug use 8 14 313 280 3 539 42 1,198
Male-to-male sexual contact
and injection drug use
20 12 230 261 3 545 38 1,109
Heterosexual contactf 3 30 1,241 427 2 325 24 2,051
     Perinatalg 0 0 8 0 0 1 0 9
     Otherh 0 2 8 3 0 6 0 20
     Subtotal 157 549 9,862 7,331 50 6,542 654 25,145
     Female sex at birth (≥13 yrs at diagnosis)e
Injection drug use 20 6 250 136 2 422 21 857
Heterosexual contactf 23 79 2,674 812 12 858 116 4,575
     Perinatalg 0 1 40 5 0 5 1 51
     Otherh 0 1 1 1 0 4 0 7
     Subtotal 43 86 2,965 954 15 1,289 138 5,490
     Child (<13 yrs at diagnosis)
     Perinatal 0 0 26 8 1 9 0 44
     Otherh 1 2 6 1 0 3 0 13
     Subtotal 1 2 32 9 1 12 0 57
Region of residencef
Northeast 7 93 1,721 1,340 4 972 134 4,271
Midwest 32 75 1,980 515 5 1,396 124 4,127
South 49 151 8,081 3,435 13 3,566 394 15,689
West 113 318 1,074 2,718 44 1,909 140 6,316
U.S. dependent areas 0 0 3 286 0 0 0 289
Total 201 637 12,859 8,294 66 7,843 792 30,692

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

aHispanic/Latino persons can be of any race.
b“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
dTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
eData include transgender and additional gender identity persons.
fSexual contact with a person known to have, or with a risk factor for, HIV infection.
gIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
hOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
iData are based on residence at time of diagnosis of HIV infection.

Table 3a. Diagnoses of HIV infection among persons aged ≥13 years, by year of diagnosis, sex assigned at birth, and selected characteristics, 2016–2020—United States
2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Male sex at birthb
    Age at diagnosis (yr)
13–14 10 0.2 13 0.3 11 0.3 12 0.3 6 0.1
15–19 1,467 13.6 1,536 14.2 1,476 13.7 1,444 13.4 1,091 10.2
20–24 6,173 53.7 5,691 50.3 5,389 48.2 5,242 47.4 4,264 38.6
25–29 6,898 59.1 6,745 56.7 6,759 56.3 6,455 53.7 5,288 44.5
30–34 4,608 41.9 4,659 42.0 4,719 42.2 4,713 41.4 4,386 37.9
35–39 3,249 31.3 3,339 31.5 3,282 30.4 3,235 29.7 2,708 24.8
40–44 2,475 25.3 2,238 23.0 2,185 22.3 2,218 22.4 1,947 19.3
45–49 2,273 21.9 2,165 20.9 2,058 20.1 1,897 18.8 1,521 15.4
50–54 2,133 19.9 1,979 18.9 1,796 17.5 1,685 16.7 1,400 13.9
55–59 1,308 12.3 1,313 12.3 1,299 12.2 1,321 12.4 1,155 11.0
60–64 734 7.9 751 7.9 723 7.4 757 7.7 616 6.2
≥65 624 2.9 612 2.7 634 2.7 610 2.5 515 2.1
    Race/ethnicity
 American Indian/Alaska Native 175 18.5 155 16.2 144 14.9 159 16.3 157 16.0
Asian 776 10.9 806 11.0 759 10.1 637 8.3 549 7.1
Black/African American 12,345 79.3 11,944 75.9 11,718 73.7 11,604 72.3 9,859 60.9
Hispanic/Latinoc 8,890 40.2 8,750 38.6 8,747 37.8 8,708 36.9 7,086 29.4
Native Hawaiian/other Pacific Islander 32 13.8 43 18.1 56 23.1 57 23.1 50 19.9
White 8,438 10.0 8,203 9.8 7,958 9.5 7,550 9.0 6,542 7.8
Multiracial 1,296 60.9 1,140 51.7 949 41.6 874 37.0 654 26.8
   Region of residenced
Northeast 4,805 20.8 4,648 20.1 4,337 18.8 4,157 18.0 3,372 14.6
Midwest 4,202 15.1 4,149 14.8 4,004 14.3 3,776 13.4 3,382 12.0
South 16,081 32.4 15,591 31.1 15,411 30.4 15,304 29.9 12,650 24.5
West 6,864 21.7 6,653 20.8 6,579 20.4 6,352 19.5 5,493 16.7
   Subtotal 31,952 24.2 31,041 23.3 30,331 22.6 29,589 21.9 24,897 18.3
Female sex at birthb
    Age at diagnosis (yr)
13–14 16 0.4 12 0.3 9 0.2 9 0.2 6 0.1
15–19 248 2.4 250 2.4 243 2.4 204 2.0 157 1.5
20–24 742 6.8 775 7.2 720 6.8 727 6.9 558 5.3
25–29 1,049 9.3 978 8.5 952 8.3 947 8.2 773 6.8
30–34 1,033 9.5 1,013 9.3 954 8.7 960 8.7 811 7.2
35–39 961 9.2 921 8.7 927 8.6 905 8.3 701 6.4
40–44 770 7.8 742 7.5 786 7.9 756 7.5 568 5.6
45–49 773 7.3 765 7.3 722 6.9 678 6.6 551 5.5
50–54 723 6.5 658 6.1 659 6.2 627 6.0 457 4.4
55–59 574 5.1 559 5.0 544 4.8 511 4.5 420 3.8
60–64 346 3.4 332 3.2 323 3.1 350 3.3 269 2.5
≥65 235 0.9 270 1.0 247 0.8 265 0.9 178 0.6
   Race/ethnicity
American Indian/Alaska Native 41 4.1 45 4.5 29 2.9 45 4.4 43 4.2
Asian 147 1.8 117 1.4 103 1.2 96 1.1 86 1.0
Black/African American 4,378 25.1 4,279 24.3 4,018 22.6 3,867 21.6 2,965 16.4
Hispanic/Latinoc 1,193 5.5 1,175 5.3 1,198 5.2 1,181 5.1 913 3.8
Native Hawaiian/other Pacific Islander 6 2.6 7 3.0 5 2.1 9 3.7 15 6.0
White 1,427 1.6 1,425 1.6 1,475 1.7 1,513 1.7 1,289 1.5
Multiracial 278 12.2 227 9.7 258 10.6 228 9.1 138 5.3
   Region of residenced
Northeast 1,393 5.6 1,329 5.4 1,220 4.9 1,148 4.6 890 3.6
Midwest 939 3.2 947 3.3 923 3.2 964 3.3 736 2.5
South 4,128 7.9 4,071 7.7 3,953 7.4 3,845 7.1 3,011 5.5
West 1,010 3.1 928 2.9 990 3.0 982 3.0 812 2.4
   Subtotal 7,470 5.4 7,275 5.2 7,086 5.1 6,939 4.9 5,449 3.8
Total 39,422 14.6 38,316 14.1 37,417 13.6 36,528 13.2 30,346 10.9

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

aRates are per 100,000 population.
bData include transgender and additional gender identity persons.
cHispanic/Latino persons can be of any race.
dData are based on residence at time of diagnosis of HIV infection.

Table 3b. Diagnoses of HIV infection among persons aged ≥13 years, by year of diagnosis, sex assigned at birth, and selected characteristics, 2016–2020—United States and 6 dependent areas
2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Male sex at birthb
    Age at diagnosis (yr)
13–14 10 0.2 13 0.3 11 0.3 12 0.3 6 0.1
15–19 1,475 13.5 1,544 14.1 1,491 13.7 1,450 13.3 1,099 10.2
20–24 6,240 53.7 5,752 50.2 5,442 48.2 5,294 47.3 4,305 38.6
25–29 6,963 59.0 6,797 56.5 6,829 56.3 6,508 53.6 5,327 44.4
30–34 4,664 42.0 4,714 42.1 4,771 42.3 4,761 41.5 4,421 37.9
35–39 3,302 31.5 3,379 31.6 3,311 30.4 3,269 29.7 2,741 24.8
40–44 2,516 25.5 2,266 23.1 2,218 22.4 2,244 22.4 1,966 19.3
45–49 2,317 22.1 2,191 20.9 2,088 20.2 1,924 18.9 1,538 15.4
50–54 2,169 20.0 2,017 19.0 1,834 17.7 1,708 16.8 1,420 14.0
55–59 1,342 12.5 1,336 12.4 1,319 12.2 1,345 12.5 1,172 11.0
60–64 753 8.0 769 8.0 738 7.5 776 7.8 629 6.2
≥65 646 2.9 629 2.8 649 2.8 629 2.6 521 2.1
    Race/ethnicity
American Indian/Alaska Native 175 155 144 159 157
Asian 777 809 763 644 549
Black/African American 12,351 11,946 11,726 11,608 9,862
Hispanic/Latinoc 9,320 9,106 9,098 9,020 7,331
Native Hawaiian/other Pacific Islander 37 44 58 60 50
White 8,440 8,206 7,961 7,555 6,542
Multiracial 1,297 1,141 951 874 654
   Region of residenced
Northeast 4,805 20.8 4,648 20.1 4,337 18.8 4,157 18.0 3,372 14.6
Midwest 4,202 15.1 4,149 14.8 4,004 14.3 3,776 13.4 3,382 12.0
South 16,081 32.4 15,591 31.1 15,411 30.4 15,304 29.9 12,650 24.5
West 6,864 21.7 6,653 20.8 6,579 20.4 6,352 19.5 5,493 16.7
U.S. dependent areas 445 29.0 366 24.2 370 25.1 331 22.4 248 16.9
   Subtotal 32,397 24.2 31,407 23.3 30,701 22.6 29,920 21.9 25,145 18.3
Female sex at birthb
    Age at diagnosis (yr)
13–14 16 0.4 12 0.3 9 0.2 9 0.2 6 0.1
15–19 250 2.4 254 2.4 245 2.3 204 2.0 157 1.5
20–24 748 6.8 780 7.2 729 6.8 732 6.8 562 5.3
25–29 1,055 9.3 989 8.5 959 8.2 953 8.2 776 6.8
30–34 1,042 9.5 1,020 9.3 960 8.7 969 8.7 812 7.1
35–39 978 9.3 933 8.7 932 8.6 910 8.3 704 6.4
40–44 786 7.8 749 7.5 794 7.9 769 7.6 574 5.6
45–49 788 7.4 780 7.3 736 7.0 688 6.6 556 5.4
50–54 732 6.5 670 6.1 670 6.2 634 6.0 463 4.4
55–59 588 5.2 571 5.0 552 4.8 524 4.6 427 3.8
60–64 354 3.4 337 3.2 328 3.1 355 3.3 272 2.5
≥65 238 0.9 274 1.0 253 0.9 273 0.9 181 0.6
    Race/ethnicity
American Indian/Alaska Native 41 45 29 45 43
Asian 147 117 103 96 86
Black/African American 4,378 4,281 4,018 3,868 2,965
Hispanic/Latinoc 1,298 1,265 1,279 1,260 954
Native Hawaiian/other Pacific Islander 6 7 5 10 15
White 1,427 1,427 1,475 1,513 1,289
Multiracial 278 227 258 228 138
    Region of residenced
Northeast 1,393 5.6 1,329 5.4 1,220 4.9 1,148 4.6 890 3.6
Midwest 939 3.2 947 3.3 923 3.2 964 3.3 736 2.5
South 4,128 7.9 4,071 7.7 3,953 7.4 3,845 7.1 3,011 5.5
West 1,010 3.1 928 2.9 990 3.0 982 3.0 812 2.4
U.S. dependent areas 105 6.1 94 5.6 81 5.0 81 4.9 41 2.5
Subtotal 7,575 5.4 7,369 5.2 7,167 5.1 7,020 4.9 5,490 3.8
Total 39,972 14.6 38,776 14.1 37,868 13.7 36,940 13.2 30,635 10.9

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

aRates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.
bData include transgender and additional gender identity persons.
cHispanic/Latino persons can be of any race.
dData are based on residence at time of diagnosis of HIV infection.

Table 4a. Diagnoses of HIV infection among transgender and additional gender identity persons aged ≥13 years, by year of diagnosis and selected characteristics, 2016–2020—United States
2016 2017 2018 2019 2020
(COVID-19 Pandemic)
No. No. No. No. No.
Transgender womana
    Age at diagnosis (yr)
13–14 0 0 0 0 0
15–19 61 57 41 40 31
20–24 201 149 163 166 145
25–29 185 171 185 165 193
30–34 90 109 95 130 125
35–39 69 55 72 62 47
40–44 27 30 32 40 37
45–49 17 21 22 21 31
50–54 9 8 7 16 16
55–59 9 7 6 7 7
60–64 3 5 2 4 5
≥65 3 0 2 1 1
   Race/ethnicity
American Indian/Alaska Native 4 2 9 5 8
Asian 8 18 9 11 16
Black/African American 343 306 302 315 309
Hispanic/Latinob 212 184 211 215 202
Native Hawaiian/other Pacific Islander 2 3 3 5 3
White 61 76 63 80 72
Multiracial 44 23 30 21 28
Exposure categoryc
Sexual contactd 620 555 563 580 576
Injection drug use 0 3 4 2 1
Sexual contactd
and injection drug use
40 38 50 54 35
Othere 14 16 10 16 26
    Region of residencef
Northeast 144 102 114 104 105
Midwest 99 99 98 85 98
South 302 278 272 287 279
West 129 133 143 176 156
    Subtotal 674 612 627 652 638
Transgender mana
    Age at diagnosis (yr)
13–14 0 0 0 0 0
15–19 1 3 2 0 1
20–24 5 7 9 11 12
25–29 5 16 18 18 10
30–34 4 1 9 12 8
35–39 3 3 4 2 5
40–44 1 0 4 0 2
45–49 2 2 1 2 1
50–54 1 0 1 0 1
55–59 0 1 0 0 0
60–64 0 0 0 0 0
≥65 0 0 0 0 0
    Race/ethnicity
American Indian/Alaska Native 0 0 0 0 0
Asian 1 2 0 1 0
Black/African American 5 11 18 18 11
Hispanic/Latinob 7 6 10 12 10
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 6 11 18 10 15
Multiracial 3 3 2 4 4
Exposure categoryc
     Sexual contactd 20 28 40 36 29
     Injection drug use 0 1 2 1 1
 Sexual contactd
and injection drug use
1 1 2 2 5
     Othere 1 3 4 6 5
    Region of residencef
Northeast 2 5 7 6 8
Midwest 5 8 7 6 2
South 6 12 16 17 24
West 9 8 18 16 6
    Subtotal 22 33 48 45 40
Additional gender identityg
    Age at diagnosis (yr)
13–14 0 0 0 0 0
15–19 1 1 4 3 1
20–24 4 2 5 8 7
25–29 4 3 4 6 6
30–34 1 3 1 3 1
35–39 0 4 1 2 2
40–44 0 0 0 0 0
45–49 0 2 0 0 0
50–54 0 0 0 1 0
55–59 1 0 0 0 0
60–64 0 0 0 0 0
≥65 0 0 0 0 0
    Race/ethnicity
American Indian/Alaska Native 0 0 1 0 0
Asian 0 1 2 0 1
Black/African American 5 6 5 8 8
Hispanic/Latinob 3 5 2 6 4
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 2 3 3 5 4
Multiracial 1 0 2 4 0
Exposure categoryc
    Sexual contactd 9 14 15 21 14
    Injection drug use 0 0 0 0 0
Sexual contactd
and injection drug use
2 0 0 1 1
    Othere 0 1 0 1 2
    Region of residencef
Northeast 4 9 10 8 2
Midwest 1 2 0 7 5
South 4 4 3 4 5
West 2 0 2 4 5
    Subtotal 11 15 15 23 17
Total 707 660 690 720 695

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Additional gender identity not included due to small numbers. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

a“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
bHispanic/Latino persons can be of any race.
cRisk factor data for transgender and additional gender identity adults and adolescents are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
dFor persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
eOther risk factors including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
fData are based on residence at time of diagnosis of HIV infection.
gAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 4b. Diagnoses of HIV infection among transgender and additional gender identity persons aged ≥13 years, by year of diagnosis and selected characteristics, 2016–2020—United States and 6 dependent areas
2016 2017 2018 2019 2020
(COVID-19 Pandemic)
No. No. No. No. No.
Transgender womana
    Age at diagnosis (yr)
13–14 0 0 0 0 0
15–19 61 57 41 40 31
20–24 202 150 164 167 146
25–29 186 172 186 166 193
30–34 91 109 95 130 126
35–39 69 55 72 62 47
40–44 27 30 32 40 37
45–49 17 21 22 21 31
50–54 9 8 7 16 16
55–59 9 7 6 7 7
60–64 3 5 2 4 5
≥65 3 0 2 1 1
    Race/ethnicity
American Indian/Alaska Native 4 2 9 5 8
Asian 8 18 9 11 16
Black/African American 343 306 302 315 309
Hispanic/Latinob 215 186 213 217 204
Native Hawaiian/other Pacific Islander 2 3 3 5 3
White 61 76 63 80 72
Multiracial 44 23 30 21 28
Exposure categoryc
     Sexual contactd 623 557 565 582 578
     Injection drug use 0 3 4 2 1
 Sexual contactd
and injection drug use
40 38 50 54 35
     Othere 14 16 10 16 26
    Region of residencef
Northeast 144 102 114 104 105
Midwest 99 99 98 85 98
South 302 278 272 287 279
West 129 133 143 176 156
US dependent areas 3 2 2 2 2
    Subtotal 677 614 629 654 640
Transgender mana
    Age at diagnosis (yr)
13–14 0 0 0 0 0
15–19 1 3 2 0 1
20–24 5 7 9 11 12
25–29 5 16 18 18 10
30–34 4 1 9 12 8
35–39 3 3 5 2 5
40–44 1 0 4 0 2
45–49 2 2 1 2 1
50–54 1 0 1 0 1
55–59 0 1 0 0 0
60–64 0 0 0 0 0
≥65 0 0 0 0 0
    Race/ethnicity
American Indian/Alaska Native 0 0 0 0 0
Asian 1 2 0 1 0
Black/African American 5 11 18 18 11
Hispanic/Latinob 7 6 11 12 10
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 6 11 18 10 15
Multiracial 3 3 2 4 4
Exposure categoryc
     Sexual contactd 20 28 41 36 29
     Injection drug use 0 1 2 1 1
Sexual contactd
and injection drug use
1 1 2 2 5
     Othere 1 3 4 6 5
    Region of residencef
Northeast 2 5 7 6 8
Midwest 5 8 7 6 2
South 6 12 16 17 24
West 9 8 18 16 6
US dependent areas 0 0 1 0 0
    Subtotal 22 33 49 45 40
Additional gender identityg
    Age at diagnosis (yr)
13–14 0 0 0 0 0
15–19 1 1 4 3 1
20–24 4 2 5 8 7
25–29 4 3 4 6 6
30–34 1 3 1 3 1
35–39 0 4 1 2 2
40–44 0 0 0 0 0
45–49 0 2 0 0 0
50–54 0 0 0 1 0
55–59 1 0 0 0 0
60–64 0 0 0 0 0
≥65 0 0 0 0 0
    Race/ethnicity
American Indian/Alaska Native 0 0 1 0 0
Asian 0 1 2 0 1
Black/African American 5 6 5 8 8
Hispanic/Latinob 3 5 2 6 4
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 2 3 3 5 4
Multiracial 1 0 2 4 0
Exposure categoryc
     Sexual contactd 9 14 15 21 14
     Injection drug use 0 0 0 0 0
Sexual contactd
and injection drug use
2 0 0 1 1
     Othere 0 1 0 1 2
    Region of residencef
Northeast 4 9 10 8 2
Midwest 1 2 0 7 5
South 4 4 3 4 5
West 2 0 2 4 5
US dependent areas 0 0 0 0 0
Subtotal 11 15 15 23 17
Total 710 662 693 722 697

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Additional gender identity not included due to small numbers. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

a“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
bHispanic/Latino persons can be of any race.
cRisk factor data for transgender and additional gender identity adults and adolescents are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
dFor persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
eOther risk factors including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
fData are based on residence at time of diagnosis of HIV infection.
gAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 5a. Diagnoses of HIV infection among males, based on sex assigned at birth, attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2016–2020—United States
Male-to-male sexual contact Male-to-male sexual contact and injection drug use
2016 2017 2018 2019 2020 (COVID-19 Pandemic) 2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. No. No. No. No. No. No. No. No. No.
American Indian/Alaska Native
    Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 2 2 7 7 5 0 0 0 0 0
20–24 24 18 25 25 23 4 3 2 3 4
25–29 36 31 21 28 25 5 5 7 6 4
30–34 28 18 18 16 20 3 6 6 1 3
35–39 12 14 9 19 14 2 1 2 3 5
40–44 14 11 7 6 14 0 2 1 0 3
45–49 6 6 7 7 7 0 1 2 1 1
50–54 5 8 7 9 10 1 0 0 1 1
55–59 3 2 3 3 5 0 0 0 0 0
60–64 3 2 0 2 2 0 1 0 0 0
≥65 1 1 3 0 1 0 1 0 0 0
   Region of residencea
Northeast 7 2 5 4 6 0 0 0 0 0
Midwest 12 10 13 8 11 1 3 5 2 4
South 33 26 17 41 35 6 9 4 3 0
West 82 75 72 67 74 9 7 13 11 16
    Total 135 112 106 120 126 16 20 21 16 20
Asian
    Age at diagnosis (yr)
13–14 0 0 1 0 0 0 0 0 0 0
15–19 20 25 24 18 17 0 0 0 0 0
20–24 109 148 108 91 64 4 3 1 2 1
25–29 155 151 168 131 124 2 4 3 2 4
30–34 123 113 119 94 89 2 5 3 6 4
35–39 78 90 74 74 52 1 0 3 2 0
40–44 86 74 62 43 44 1 1 1 0 2
45–49 50 65 58 51 42 1 3 0 1 1
50–54 31 35 24 35 25 1 0 0 0 0
55–59 19 20 19 18 14 0 0 0 0 0
60–64 8 8 9 7 12 0 0 0 0 0
≥65 10 7 10 9 8 1 0 0 0 0
    Region of residencea
Northeast 134 129 130 105 73 3 3 2 2 0
Midwest 59 76 66 53 57 4 0 0 1 1
South 147 153 173 145 110 1 1 1 4 1
West 348 379 306 268 251 6 12 10 7 10
    Total 689 737 675 570 491 13 16 13 14 12
Black/African American
    Age at diagnosis (yr)
13–14 4 4 7 7 2 0 0 0 0 0
15–19 802 855 811 802 608 16 13 10 10 10
20–24 2,815 2,530 2,425 2,399 2,076 65 43 51 39 42
25–29 2,544 2,492 2,513 2,353 1,982 78 71 78 88 56
30–34 1,210 1,330 1,274 1,425 1,466 50 49 49 66 55
35–39 721 761 744 744 670 32 37 27 40 22
40–44 447 442 448 469 397 16 17 20 23 15
45–49 377 356 354 339 269 20 12 10 18 11
50–54 346 321 309 281 244 13 24 18 17 9
55–59 202 206 200 212 203 9 12 10 8 6
60–64 98 111 101 114 92 7 5 5 6 2
≥65 64 67 79 80 55 4 5 4 2 2
    Region of residencea
Northeast 1,144 1,143 1,082 1,108 941 38 36 50 41 36
Midwest 1,584 1,502 1,461 1,415 1,323 66 51 52 46 41
South 6,064 6,013 5,892 5,899 5,079 167 150 137 175 115
West 839 819 829 803 719 40 51 44 55 37
    Total 9,630 9,476 9,264 9,226 8,062 311 288 282 318 230
Hispanic/Latinob
    Age at diagnosis (yr)
13–14 2 5 0 2 3 0 0 0 0 0
15–19 314 337 320 356 252 17 11 10 7 5
20–24 1,486 1,382 1,375 1,382 1,047 80 68 73 64 33
25–29 1,796 1,750 1,791 1,752 1,434 85 98 105 96 70
30–34 1,325 1,332 1,321 1,312 1,187 77 68 54 71 55
35–39 934 927 914 926 735 47 50 44 62 32
40–44 624 594 557 611 537 37 22 27 34 20
45–49 475 513 501 458 358 12 18 19 22 19
50–54 356 342 335 348 294 17 16 16 21 11
55–59 154 172 197 182 191 7 8 3 10 4
60–64 76 71 90 92 85 4 3 4 2 7
≥65 54 74 69 70 54 3 2 2 3 1
    Region of residencea
Northeast 1,247 1,285 1,172 1,163 924 56 40 54 60 26
Midwest 494 517 521 521 412 30 30 27 35 17
South 3,253 3,199 3,220 3,247 2,642 146 132 112 142 90
West 2,602 2,498 2,557 2,562 2,199 155 164 166 156 123
    Total 7,596 7,499 7,469 7,492 6,176 386 365 359 394 256
Native Hawaiian/other Pacific Islander
    Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 1 1 3 1 3 0 0 0 0 0
20–24 1 9 7 6 6 0 0 2 0 0
25–29 7 9 9 19 11 2 0 2 0 1
30–34 3 9 11 10 7 2 0 1 1 1
35–39 7 2 8 7 7 0 1 0 1 0
40–44 3 5 2 4 5 0 0 0 0 0
45–49 0 1 2 0 1 0 0 0 0 1
50–54 2 1 1 4 2 0 0 0 0 0
55–59 0 0 4 1 1 0 0 0 0 0
60–64 0 0 1 1 0 0 0 0 0 0
≥65 1 0 1 0 0 1 0 0 0 0
    Region of residencea
Northeast 2 3 2 2 3 1 0 0 0 0
Midwest 1 2 2 5 3 0 0 0 0 1
South 4 7 8 13 8 0 0 0 0 0
West 18 25 36 33 28 4 1 5 2 2
    Total 24 37 48 52 42 5 1 5 3 3
White
    Age at diagnosis (yr)
13–14 0 1 0 1 0 0 0 0 0 0
15–19 155 161 169 132 120 20 13 10 14 1
20–24 868 916 798 730 591 95 87 70 74 48
25–29 1,206 1,204 1,124 1,096 913 160 169 181 166 124
30–34 962 885 948 888 858 129 130 145 144 106
35–39 673 726 658 662 544 86 100 115 112 103
40–44 612 490 523 455 454 67 62 57 64 52
45–49 709 614 562 467 406 58 60 49 52 42
50–54 733 672 535 503 441 44 41 43 36 32
55–59 459 440 432 458 410 35 25 27 31 23
60–64 239 243 250 235 204 14 16 7 14 9
≥65 200 185 208 182 185 9 10 6 10 5
    Region of residencea
Northeast 953 831 749 693 583 66 81 76 61 73
Midwest 1,183 1,216 1,086 968 937 141 107 133 145 99
South 2,968 2,837 2,794 2,657 2,282 280 310 285 294 206
West 1,712 1,655 1,580 1,490 1,325 229 213 217 215 166
    Total 6,815 6,538 6,208 5,808 5,126 716 712 711 715 545
Multiracial
    Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 57 57 43 45 34 3 2 3 2 1
20–24 276 221 183 154 115 18 12 9 6 6
25–29 265 245 197 175 134 25 11 25 17 10
30–34 150 144 119 118 77 16 11 13 24 4
35–39 79 81 83 73 62 9 13 12 5 6
40–44 69 55 44 46 43 3 4 2 7 5
45–49 57 49 40 31 34 7 6 6 1 5
50–54 44 52 31 17 24 5 6 4 2 1
55–59 33 21 14 32 13 3 3 0 2 0
60–64 20 15 10 9 7 3 0 0 0 0
≥65 9 8 11 7 9 0 0 0 1 0
    Region of residencea
Northeast 205 167 136 138 94 16 10 7 7 5
Midwest 142 151 112 77 83 18 10 14 13 7
South 497 451 370 363 266 36 35 29 31 16
West 216 178 157 127 106 22 14 23 15 11
    Total 1,059 947 775 706 550 92 69 73 66 38
Total
    Age at diagnosis (yr)
13–14 5 10 8 10 5 0 0 0 0 0
15–19 1,351 1,439 1,376 1,359 1,038 55 39 32 33 17
20–24 5,579 5,224 4,920 4,787 3,921 265 215 208 189 134
25–29 6,010 5,881 5,823 5,553 4,622 357 359 402 375 269
30–34 3,801 3,831 3,810 3,863 3,704 279 269 271 312 227
35–39 2,504 2,600 2,490 2,505 2,083 177 201 204 224 169
40–44 1,854 1,670 1,643 1,634 1,494 125 108 108 128 96
45–49 1,674 1,605 1,522 1,353 1,116 99 100 87 96 79
50–54 1,517 1,432 1,242 1,196 1,040 82 87 82 77 54
55–59 870 862 869 905 836 54 49 41 50 33
60–64 444 451 460 460 401 29 25 18 23 19
≥65 339 342 380 349 312 18 18 13 17 8
    Region of residencea
Northeast 3,691 3,559 3,274 3,213 2,624 178 170 188 172 141
Midwest 3,475 3,474 3,261 3,047 2,826 260 201 232 242 171
South 12,966 12,684 12,473 12,364 10,420 636 637 567 650 428
West 5,816 5,629 5,537 5,350 4,702 465 462 478 461 365
    Total 25,948 25,346 24,545 23,974 20,572 1,539 1,470 1,465 1,524 1,105

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as male-to-male sexual contact or male-to-male sexual contact and injection drug use are presented based on sex at birth and include transgender and additional gender identity persons.

a Data are based on residence at time of diagnosis of HIV infection.
bHispanic/Latino persons can be of any race.

Table 5b. Diagnoses of HIV infection among males, based on sex assigned at birth, attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2016–2020—United States and 6 dependent areas
Male-to-male sexual contact Male-to-male sexual contact and injection drug use
2016 2017 2018 2019 2020 (COVID-19 Pandemic) 2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. No. No. No. No. No. No. No. No. No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 2 2 7 7 5 0 0 0 0 0
20–24 24 18 25 25 23 4 3 2 3 4
25–29 36 31 21 28 25 5 5 7 6 4
30–34 28 18 18 16 20 3 6 6 1 3
35–39 12 14 9 19 14 2 1 2 3 5
40–44 14 11 7 6 14 0 2 1 0 3
45–49 6 6 7 7 7 0 1 2 1 1
50–54 5 8 7 9 10 1 0 0 1 1
55–59 3 2 3 3 5 0 0 0 0 0
60–64 3 2 0 2 2 0 1 0 0 0
≥65 1 1 3 0 1 0 1 0 0 0
Region of residencea
Northeast 7 2 5 4 6 0 0 0 0 0
Midwest 12 10 13 8 11 1 3 5 2 4
South 33 26 17 41 35 6 9 4 3 0
West 82 75 72 67 74 9 7 13 11 16
U.S. dependent areas 0 0 0 0 0 0 0 0 0 0
Total 135 112 106 120 126 16 20 21 16 20
Asian
Age at diagnosis (yr)
13–14 0 0 1 0 0 0 0 0 0 0
15–19 20 25 24 18 17 0 0 0 0 0
20–24 109 148 108 91 64 4 3 1 2 1
25–29 155 151 169 134 124 2 4 3 3 4
30–34 123 115 121 95 89 2 5 3 6 4
35–39 79 91 74 75 52 1 0 3 2 0
40–44 86 74 62 43 44 1 1 1 0 2
45–49 50 65 58 51 42 1 3 0 1 1
50–54 31 35 24 35 25 1 0 0 1 0
55–59 19 20 19 18 14 0 0 0 0 0
60–64 8 8 9 7 12 0 0 0 0 0
≥65 10 7 10 9 8 1 0 0 0 0
Region of residencea
Northeast 134 129 130 105 73 3 3 2 2 0
Midwest 59 76 66 53 57 4 0 0 1 1
South 147 153 173 145 110 1 1 1 4 1
West 348 379 306 268 251 6 12 10 7 10
U.S. dependent areas 1 3 4 6 0 0 0 0 1 0
Total 690 740 679 576 491 13 16 13 15 12
Black/African American
Age at diagnosis (yr)
13–14 4 4 7 7 2 0 0 0 0 0
15–19 802 855 811 802 610 16 13 10 10 10
20–24 2,816 2,530 2,425 2,400 2,076 65 43 51 39 42
25–29 2,544 2,492 2,515 2,353 1,982 78 71 78 88 56
30–34 1,211 1,330 1,275 1,425 1,466 50 49 49 66 55
35–39 721 761 744 744 670 32 37 27 40 22
40–44 448 443 449 469 397 16 17 20 23 15
45–49 377 356 354 339 269 20 12 10 18 11
50–54 346 321 309 281 244 13 24 18 17 9
55–59 202 206 200 212 203 9 12 10 8 6
60–64 98 111 101 114 92 7 5 5 6 2
≥65 64 67 79 80 55 4 5 4 2 2
Region of residencea
Northeast 1,144 1,143 1,082 1,108 941 38 36 50 41 36
Midwest 1,584 1,502 1,461 1,415 1,323 66 51 52 46 41
South 6,064 6,013 5,892 5,899 5,079 167 150 137 175 115
West 839 819 829 803 719 40 51 44 55 37
U.S. dependent areas 3 1 4 1 2 0 0 0 0 0
Total 9,633 9,478 9,268 9,227 8,064 311 288 282 318 230
Hispanic/Latinob
Age at diagnosis (yr)
13–14 2 5 0 2 3 0 0 0 0 0
15–19 321 344 334 362 258 18 11 10 7 5
20–24 1,547 1,432 1,425 1,426 1,085 80 70 74 67 34
25–29 1,853 1,792 1,844 1,796 1,467 87 102 108 97 72
30–34 1,367 1,369 1,356 1,349 1,217 79 70 57 73 55
35–39 970 948 934 950 761 50 52 45 64 34
40–44 644 609 579 624 547 38 23 28 35 20
45–49 495 529 523 471 370 13 21 19 22 19
50–54 379 364 351 363 310 17 16 17 21 11
55–59 169 181 207 193 197 7 8 5 11 4
60–64 78 75 97 101 89 4 3 5 2 7
≥65 56 76 72 73 56 3 2 3 4 1
Region of residencea
Northeast 1,247 1,285 1,172 1,163 924 56 40 54 60 26
Midwest 494 517 521 521 412 30 30 27 35 17
South 3,253 3,199 3,220 3,247 2,642 146 132 112 142 90
West 2,602 2,498 2,557 2,562 2,199 155 164 166 156 123
U.S. dependent areas 285 226 253 217 183 11 13 12 10 5
Total 7,881 7,725 7,722 7,709 6,359 397 378 371 404 261
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 1 1 3 1 3 0 0 0 0 0
20–24 2 9 7 6 6 0 0 2 0 0
25–29 7 9 9 19 11 3 0 2 1 1
30–34 5 9 11 10 7 2 0 1 1 1
35–39 7 2 9 7 7 0 1 0 1 0
40–44 3 5 2 5 5 0 0 0 0 0
45–49 0 1 2 0 1 0 0 0 0 1
50–54 2 1 1 5 2 0 0 0 0 0
55–59 0 0 4 1 1 0 0 0 0 0
60–64 0 0 1 1 0 0 0 0 0 0
≥65 1 0 1 0 0 1 0 0 0 0
Region of residencea
Northeast 2 3 2 2 3 1 0 0 0 0
Midwest 1 2 2 5 3 0 0 0 0 1
South 4 7 8 13 8 0 0 0 0 0
West 18 25 36 33 28 4 1 5 2 2
U.S. dependent areas 3 0 1 2 0 1 0 0 1 0
Total 28 37 49 54 42 6 1 5 4 3
White
Age at diagnosis (yr)
13–14 0 1 0 1 0 0 0 0 0 0
15–19 155 161 169 132 120 20 13 10 14 1
20–24 869 916 798 730 591 95 87 70 74 48
25–29 1,206 1,204 1,124 1,096 913 160 169 181 166 124
30–34 963 885 948 890 858 129 130 145 144 106
35–39 673 728 658 662 544 86 100 115 112 103
40–44 612 490 524 455 454 67 62 57 64 52
45–49 709 614 562 467 406 58 60 49 52 42
50–54 733 673 536 503 441 44 41 43 36 32
55–59 459 440 433 458 410 35 25 27 31 23
60–64 239 243 250 236 204 14 16 7 14 9
≥65 200 185 208 183 185 9 10 6 10 5
Region of residencea
Northeast 953 831 749 693 583 66 81 76 61 73
Midwest 1,183 1,216 1,086 968 937 141 107 133 145 99
South 2,968 2,837 2,794 2,657 2,282 280 310 285 294 206
West 1,712 1,655 1,580 1,490 1,325 229 213 217 215 166
U.S. dependent areas 2 3 3 4 0 0 0 0 0 0
Total 6,817 6,541 6,211 5,812 5,126 716 712 711 715 545
Multiracial
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 57 57 43 45 34 3 2 3 2 1
20–24 276 221 183 154 115 18 12 9 6 6
25–29 265 245 197 175 134 25 11 25 17 10
30–34 150 144 119 118 77 16 11 13 24 4
35–39 79 81 83 73 62 9 13 12 5 6
40–44 69 55 44 46 43 3 4 2 7 5
45–49 57 49 40 31 34 7 6 6 1 5
50–54 44 52 31 17 24 5 6 4 2 1
55–59 33 21 14 32 13 3 3 0 2 0
60–64 21 15 10 9 7 3 0 0 0 0
≥65 9 8 11 7 9 0 0 0 1 0
Region of residencea
Northeast 205 167 136 138 94 16 10 7 7 5
Midwest 142 151 112 77 83 18 10 14 13 7
South 497 451 370 363 266 36 35 29 31 16
West 216 178 157 127 106 22 14 23 15 11
U.S. dependent areas 1 1 0 0 0 0 0 0 0 0
Total 1,060 948 775 706 550 92 69 73 66 38
Total
Age at diagnosis (yr)
13–14 5 10 8 10 5 0 0 0 0 0
15–19 1,358 1,446 1,390 1,365 1,046 56 39 32 33 17
20–24 5,642 5,274 4,970 4,832 3,958 265 217 209 192 135
25–29 6,067 5,923 5,879 5,600 4,655 361 363 405 378 272
30–34 3,847 3,870 3,848 3,902 3,734 281 272 274 315 227
35–39 2,540 2,626 2,510 2,530 2,109 180 204 205 226 170
40–44 1,876 1,686 1,668 1,648 1,505 126 108 108 128 96
45–49 1,694 1,621 1,544 1,366 1,128 100 102 87 96 79
50–54 1,540 1,455 1,260 1,213 1,056 82 87 82 77 54
55–59 885 871 881 917 842 54 49 42 51 33
60–64 448 455 468 469 406 29 25 19 23 19
≥65 342 344 383 352 314 18 18 14 18 8
Region of residencea
Northeast 3,691 3,559 3,274 3,213 2,624 178 170 188 172 141
Midwest 3,475 3,474 3,261 3,047 2,826 260 201 232 242 171
South 12,966 12,684 12,473 12,364 10,420 636 637 567 650 428
West 5,816 5,629 5,537 5,350 4,702 465 462 478 461 365
U.S. dependent areas 295 234 264 230 185 12 13 12 12 5
Total 26,244 25,580 24,810 24,204 20,758 1,551 1,483 1,477 1,536 1,109

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as male-to-male sexual contact or male-to-male sexual contact and injection drug use are presented based on sex at birth and include transgender and additional gender identity persons.

a Data are based on residence at time of diagnosis of HIV infection.
bHispanic/Latino persons can be of any race.

Table 6a. Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, sex assigned at birth, race/ethnicity, and selected characteristics, 2016–2020—United States
Male sex at birth Female sex at birth
2016 2017 2018 2019 2020 (COVID-19 Pandemic) 2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. No. No. No. No. No. No. No. No. No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 1 0 0 0 0 0 0 0
20–24 3 0 0 2 1 1 1 0 2 0
25–29 5 6 1 1 0 3 2 3 1 6
30–34 0 3 3 2 3 1 1 2 2 3
35–39 1 0 0 4 1 2 3 3 7 4
40–44 2 1 0 3 0 1 2 1 3 3
45–49 2 0 1 1 0 2 2 2 1 1
50–54 0 3 2 1 2 4 2 2 2 1
55–59 3 1 0 0 0 0 0 1 0 0
60–64 0 1 0 0 0 0 0 1 0 0
≥65 0 1 0 0 0 0 1 0 1 1
Region of residencea
Northeast 0 1 0 0 0 1 1 0 0 0
Midwest 0 2 2 4 3 1 1 2 5 10
South 3 2 1 2 3 1 4 5 7 2
West 14 11 5 8 2 12 9 6 8 8
Total 17 16 9 15 8 15 15 14 19 20
Asian
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 0 0 0
20–24 0 1 1 0 0 1 0 0 0 0
25–29 2 1 0 2 1 1 2 0 0 0
30–34 1 0 2 0 2 1 0 2 2 2
35–39 3 2 0 3 1 1 1 1 1 1
40–44 1 3 2 1 2 1 0 0 1 0
45–49 3 2 2 3 3 2 0 0 1 1
50–54 1 1 1 3 2 0 1 0 0 1
55–59 1 1 0 1 1 0 0 0 0 0
60–64 0 0 1 0 2 0 1 0 0 0
≥65 1 0 1 1 1 0 0 0 0 1
Region of residencea
Northeast 4 4 5 4 3 3 1 1 1 1
Midwest 2 0 1 3 3 0 1 0 0 0
South 2 2 4 3 1 2 2 2 1 2
West 6 5 1 6 8 3 4 2 4 3
Total 14 10 11 15 14 8 7 5 6 6
Black/African American
Age at diagnosis (yr)
13–14 0 0 0 0 0 1 0 0 1 0
15–19 4 6 4 4 3 7 8 7 7 7
20–24 20 16 21 22 20 22 30 24 29 20
25–29 29 35 46 51 35 39 38 29 44 34
30–34 33 49 51 57 41 42 40 40 43 36
35–39 44 41 59 45 37 36 39 35 44 30
40–44 44 31 35 44 26 29 40 30 34 18
45–49 41 46 43 31 29 33 41 36 40 25
50–54 57 47 50 40 30 53 40 41 30 24
55–59 43 53 51 39 39 42 31 39 31 31
60–64 36 35 36 42 23 28 25 26 29 16
≥65 29 31 35 33 30 18 19 16 21 10
Region of residencea
Northeast 103 123 122 117 90 76 92 80 94 50
Midwest 54 61 59 51 42 54 60 46 51 46
South 183 173 204 199 155 182 164 162 164 125
West 39 32 45 40 26 39 35 37 42 29
Total 379 389 430 407 313 350 351 324 351 250
Hispanic/Latinob
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 1
15–19 2 4 3 1 2 4 4 2 6 2
20–24 18 20 24 17 15 13 19 22 19 8
25–29 37 40 34 44 37 31 18 20 21 18
30–34 48 58 63 44 36 25 29 27 23 26
35–39 43 44 46 48 39 14 24 26 35 23
40–44 23 43 35 38 42 17 21 15 13 16
45–49 34 38 35 25 26 17 16 21 15 9
50–54 39 41 39 27 27 17 14 14 17 11
55–59 25 23 25 25 13 13 7 9 9 9
60–64 12 12 14 13 12 7 7 9 6 9
≥65 13 13 10 12 14 7 4 6 5 3
Region of residencea
Northeast 97 115 109 85 74 52 47 55 51 38
Midwest 14 16 14 10 13 11 11 9 12 6
South 85 93 95 88 76 54 53 49 55 34
West 98 114 110 111 98 48 52 58 52 56
Total 295 338 329 295 261 165 163 170 170 134
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 0 0 0
20–24 0 0 0 0 0 0 0 0 0 0
25–29 0 0 0 1 1 0 0 0 0 0
30–34 0 0 0 0 0 0 0 0 0 0
35–39 0 0 0 0 1 0 0 0 0 0
40–44 0 0 0 0 0 0 0 0 0 0
45–49 0 0 1 0 0 0 0 0 0 1
50–54 0 1 0 0 0 2 0 0 0 0
55–59 0 0 0 0 0 0 0 0 0 0
60–64 0 0 0 0 0 0 0 0 0 1
≥65 0 0 0 0 0 0 0 0 0 0
Region of residencea
Northeast 0 0 0 0 0 0 0 0 0 0
Midwest 0 0 0 1 1 0 0 0 0 0
South 0 0 0 0 0 0 0 0 0 1
West 0 1 1 0 1 2 0 0 0 2
Total 0 1 1 1 3 2 0 0 0 2
White
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 3 3 4 0 4 5 9 8 6 2
20–24 30 35 36 44 21 44 51 46 44 17
25–29 77 86 99 103 81 93 91 87 89 74
30–34 61 89 107 112 113 70 99 99 106 84
35–39 65 74 113 102 116 59 79 96 97 69
40–44 44 49 63 71 61 45 52 71 75 46
45–49 49 57 51 69 52 45 40 46 55 38
50–54 53 36 50 43 32 38 41 41 38 37
55–59 25 36 35 43 36 20 34 27 35 32
60–64 17 18 22 17 13 16 9 10 12 16
≥65 17 17 10 9 8 10 6 6 5 7
Region of residencea
Northeast 82 93 115 96 99 87 90 92 78 59
Midwest 80 92 118 105 89 85 92 109 98 63
South 159 196 223 276 243 187 234 224 279 221
West 120 119 134 133 108 85 95 112 108 80
Total 440 501 589 611 539 445 510 537 563 422
Multiracial
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 1 0 0 0 0 1 2 3 2 0
20–24 3 2 5 4 5 4 6 9 2 2
25–29 10 8 5 3 4 6 8 12 9 4
30–34 1 6 4 12 10 3 4 6 4 2
35–39 7 5 4 2 10 9 6 6 8 3
40–44 6 4 4 2 2 5 5 5 8 3
45–49 2 5 3 3 3 7 3 5 3 3
50–54 8 3 7 5 3 5 3 5 5 1
55–59 5 2 4 2 2 6 3 1 2 1
60–64 3 1 1 1 2 1 0 3 1 2
≥65 1 2 1 2 0 1 0 1 1 0
Region of residencea
Northeast 8 10 6 15 7 12 13 10 10 2
Midwest 3 9 8 7 7 6 4 9 11 4
South 16 11 13 10 22 20 15 24 19 11
West 18 8 11 6 5 11 7 12 6 4
Total 44 37 38 37 42 49 39 55 46 21
Total
Age at diagnosis (yr)
13–14 0 0 0 0 0 1 1 0 1 1
15–19 11 13 13 5 9 17 23 19 21 11
20–24 73 73 87 88 62 86 107 101 96 48
25–29 158 176 186 207 160 174 159 150 164 137
30–34 144 205 230 228 204 143 174 176 179 153
35–39 163 166 223 204 205 122 152 166 192 128
40–44 120 130 140 159 133 98 120 123 133 86
45–49 131 149 134 132 112 104 102 110 115 78
50–54 158 133 149 119 95 120 101 103 93 75
55–59 101 116 116 110 92 81 75 77 78 73
60–64 68 67 74 74 53 52 42 49 48 44
≥65 62 64 57 57 53 36 30 30 34 21
Region of residencea
Northeast 293 346 358 317 273 230 244 239 234 150
Midwest 153 180 202 182 158 157 169 174 176 128
South 448 477 540 579 501 446 471 465 523 396
West 295 290 307 304 247 201 202 227 221 181
Total 1,189 1,292 1,407 1,381 1,178 1,034 1,086 1,105 1,154 855

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column total.
Persons whose transmission category is classified as injection drug use include transgender and additional gender identity persons.

aData are based on residence at time of diagnosis of HIV infection.
bHispanic/Latino persons can be of any race.

Table 6b. Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, sex assigned at birth, race/ethnicity, and selected characteristics, 2016–2020—United States and 6 dependent areas
Male sex at birth Female sex at birth
2016 2017 2018 2019 2020 (COVID-19 Pandemic) 2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. No. No. No. No. No. No. No. No. No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 1 0 0 0 0 0 0 0
20–24 3 0 0 2 1 1 1 0 2 0
25–29 5 6 1 1 0 3 2 3 1 6
30–34 0 3 3 2 3 1 1 2 2 3
35–39 1 0 0 4 1 2 3 3 7 4
40–44 2 1 0 3 0 1 2 1 3 3
45–49 2 0 1 1 0 2 2 2 1 1
50–54 0 3 2 1 2 4 2 2 2 1
55–59 3 1 0 0 0 0 0 1 0 0
60–64 0 1 0 0 0 0 0 1 0 0
≥65 0 1 0 0 0 0 1 0 1 1
Region of residencea
Northeast 0 1 0 0 0 1 1 0 0 0
Midwest 0 2 2 4 3 1 1 2 5 10
South 3 2 1 2 3 1 4 5 7 2
West 14 11 5 8 2 12 9 6 8 8
U.S. dependent areas 0 0 0 0 0 0 0 0 0 0
Total 17 16 9 15 8 15 15 14 19 20
Asian
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 0 0 0
20–24 0 1 1 0 0 1 0 0 0 0
25–29 2 1 0 2 1 1 2 0 0 0
30–34 1 0 2 0 2 1 0 2 2 2
35–39 3 2 0 3 1 1 1 1 1 1
40–44 1 3 2 1 2 1 0 0 1 0
45–49 3 2 2 3 3 2 0 0 1 1
50–54 1 1 1 3 2 0 1 0 0 1
55–59 1 1 0 1 1 0 0 0 0 0
60–64 0 0 1 0 2 0 1 0 0 0
≥65 1 0 1 1 1 0 0 0 0 1
Region of residencea
Northeast 4 4 5 4 3 3 1 1 1 1
Midwest 2 0 1 3 3 0 1 0 0 0
South 2 2 4 3 1 2 2 2 1 2
West 6 5 1 6 8 3 4 2 4 3
U.S. dependent areas 0 0 0 0 0 0 0 0 0 0
Total 14 10 11 16 14 8 7 5 6 6
Black/African American
Age at diagnosis (yr)
13–14 0 0 0 0 0 1 0 0 1 0
15–19 4 6 4 4 3 7 8 7 7 7
20–24 20 16 21 22 20 22 30 24 29 20
25–29 29 35 46 51 35 39 38 29 44 34
30–34 33 49 51 57 41 42 40 40 43 36
35–39 44 41 59 45 37 36 39 35 44 30
40–44 44 31 35 44 26 29 40 30 34 18
45–49 41 46 43 31 29 33 41 36 40 25
50–54 57 47 50 40 30 53 40 41 30 24
55–59 43 53 52 40 39 42 31 39 31 31
60–64 36 35 36 42 23 28 25 26 29 16
≥65 29 31 35 33 30 18 19 16 21 10
Region of residencea
Northeast 103 123 122 117 90 76 92 80 94 50
Midwest 54 61 59 51 42 54 60 46 51 46
South 183 173 204 199 155 182 164 162 164 125
West 39 32 45 40 26 39 35 37 42 29
U.S. dependent areas 1 0 1 1 0 0 0 0 0 0
Total 380 389 431 409 313 350 351 324 351 250
Hispanic/Latinob
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 1
15–19 2 4 3 1 2 4 4 2 6 2
20–24 20 20 24 17 15 14 19 22 19 8
25–29 38 42 36 45 37 32 18 20 21 18
30–34 49 63 65 44 39 26 29 28 23 26
35–39 48 45 47 53 41 16 26 26 36 23
40–44 27 44 40 42 47 19 21 15 13 17
45–49 39 41 38 27 28 18 19 21 17 9
50–54 42 51 44 29 27 19 15 14 18 12
55–59 32 28 26 26 17 13 8 9 10 9
60–64 16 16 16 16 14 9 8 9 6 9
≥65 16 17 12 17 15 7 4 6 5 3
Region of residencea
Northeast 97 115 109 85 74 52 47 55 51 38
Midwest 14 16 14 10 13 11 11 9 12 6
South 85 93 95 88 76 54 53 49 55 34
West 98 114 110 111 98 48 52 58 52 56
U.S. dependent areas 35 34 23 23 19 12 9 2 6 2
Total 329 371 352 318 280 177 172 172 175 136
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 0 0 0
20–24 0 0 0 0 0 0 0 0 0 0
25–29 0 0 0 1 1 0 0 0 0 0
30–34 0 0 0 0 0 0 0 0 0 0
35–39 0 0 0 0 1 0 0 0 0 0
40–44 0 0 0 0 0 0 0 0 0 0
45–49 0 0 1 0 0 0 0 0 0 1
50–54 0 1 0 0 0 2 0 0 0 0
55–59 0 0 0 0 0 0 0 0 0 0
60–64 0 0 0 0 0 0 0 0 0 1
≥65 0 0 0 0 0 0 0 0 0 0
Region of residencea
Northeast 0 0 0 0 0 0 0 0 0 0
Midwest 0 0 0 1 1 0 0 0 0 0
South 0 0 0 0 0 0 0 0 0 1
West 0 1 1 0 1 2 0 0 0 2
U.S. dependent areas 0 0 0 0 0 0 0 0 0 0
Total 0 1 2 1 3 2 0 0 0 2
White
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 3 3 4 0 4 5 9 8 6 2
20–24 30 35 36 44 21 44 51 46 44 17
25–29 77 86 99 103 81 93 91 87 89 74
30–34 61 89 107 112 113 70 99 99 106 84
35–39 65 74 113 102 116 59 79 96 97 69
40–44 44 49 63 71 61 45 52 71 75 46
45–49 49 57 51 69 52 45 40 46 55 38
50–54 53 36 50 43 32 38 41 41 38 37
55–59 25 36 35 43 36 20 34 27 35 32
60–64 17 18 22 17 13 16 9 10 12 16
≥65 17 17 10 9 8 10 6 6 5 7
Region of residencea
Northeast 82 93 115 96 99 87 90 92 78 59
Midwest 80 92 118 105 89 85 92 109 98 63
South 159 196 223 276 243 187 234 224 279 221
West 120 119 134 133 108 85 95 112 108 80
U.S. dependent areas 0 0 0 0 0 0 0 0 0 0
Total 440 501 589 611 539 445 511 537 563 422
Multiracial
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 1 0 0 0 0 1 2 3 2 0
20–24 3 2 5 4 5 4 6 9 2 2
25–29 10 8 5 3 4 6 8 12 9 4
30–34 1 6 4 12 10 3 4 6 4 2
35–39 7 5 4 2 10 9 6 6 8 3
40–44 6 4 4 2 2 5 5 5 8 3
45–49 2 5 3 3 3 7 3 5 3 3
50–54 8 3 7 5 3 5 3 5 5 1
55–59 5 2 4 2 2 6 3 1 2 1
60–64 3 1 1 1 2 1 0 3 1 2
≥65 1 2 1 2 0 1 0 1 1 0
Region of residencea
Northeast 8 10 6 15 7 12 13 10 10 2
Midwest 3 9 8 7 7 6 4 9 11 4
South 16 11 13 10 22 20 15 24 19 11
West 18 8 11 6 5 11 7 12 6 4
U.S. dependent areas 0 0 0 0 0 0 0 0 0 0
Total 44 37 38 37 42 49 39 55 46 21
Total
Age at diagnosis (yr)
13–14 0 0 0 0 0 1 1 0 1 1
15–19 11 13 13 5 9 17 24 19 21 11
20–24 75 73 87 89 62 87 107 101 96 48
25–29 160 178 188 208 160 175 159 150 164 137
30–34 145 210 232 228 207 144 174 177 179 153
35–39 168 167 224 208 208 124 154 166 193 128
40–44 124 131 145 163 138 100 120 123 133 87
45–49 136 152 137 134 115 105 105 111 117 78
50–54 161 142 154 121 95 122 102 103 94 76
55–59 109 120 118 113 95 81 76 77 79 73
60–64 71 71 76 76 55 54 43 49 48 44
≥65 64 68 59 61 54 36 31 30 34 21
Region of residencea
Northeast 293 346 358 317 273 230 244 239 234 150
Midwest 153 180 202 182 158 157 169 174 176 128
South 448 477 540 579 501 446 471 465 523 396
West 295 290 307 304 247 201 202 227 221 181
U.S. dependent areas 36 34 24 25 19 12 9 2 6 2
Total 1,225 1,326 1,431 1,406 1,198 1,046 1,095 1,106 1,160 857

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column total.
Persons whose transmission category is classified as injection drug use include transgender and additional gender identity persons.

aData are based on residence at time of diagnosis of HIV infection.
bHispanic/Latino persons can be of any race.

Table 7a. Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, sex assigned at birth, race/ethnicity, and selected characteristics, 2016–2020—United States
Male sex at birth Female sex at birth
2016 2017 2018 2019 2020 (COVID-19 Pandemic) 2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. No. No. No. No. No. No. No. No. No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 1 0 0 0 0 1 1 0
20–24 0 0 1 2 0 0 3 1 2 0
25–29 0 0 1 0 0 4 5 1 2 1
30–34 1 2 1 1 0 3 2 1 3 6
35–39 1 3 1 0 0 6 4 2 6 6
40–44 1 0 0 2 0 6 3 3 6 5
45–49 1 1 0 0 0 3 5 3 3 2
50–54 1 0 0 1 2 1 5 2 2 1
55–59 0 0 1 1 0 2 2 3 1 2
60–64 0 0 0 0 1 2 2 0 1 1
≥65 1 0 0 0 0 1 0 0 1 1
Region of residencea
Northeast 0 0 1 0 0 1 0 0 0 1
Midwest 1 0 1 2 0 1 3 1 9 4
South 2 3 2 6 2 9 5 8 4 7
West 5 4 3 1 1 15 22 7 12 11
Total 7 7 8 9 3 26 30 15 26 23
Asian
Age at diagnosis (yr)
13–14 0 0 0 0 0 1 0 0 0 0
15–19 0 0 0 1 1 0 2 0 1 1
20–24 3 2 5 1 1 9 5 6 6 2
25–29 2 4 1 2 3 20 18 15 8 11
30–34 11 4 8 3 2 33 8 16 16 12
35–39 13 10 8 2 3 24 24 11 16 15
40–44 4 3 11 5 2 14 11 12 6 4
45–49 8 6 6 4 4 11 12 8 14 8
50–54 4 3 6 6 4 10 12 9 4 9
55–59 3 3 2 5 4 8 7 9 8 6
60–64 4 4 5 4 2 4 6 6 7 7
≥65 6 3 6 3 5 5 5 7 4 4
Region of residencea
Northeast 8 9 13 14 3 32 16 27 13 12
Midwest 9 7 2 1 5 13 18 5 11 8
South 24 12 24 12 12 43 30 28 29 24
West 17 15 19 7 10 49 45 38 37 34
Total 58 42 58 35 30 137 109 97 90 79
Black/African American
Age at diagnosis (yr)
13–14 0 0 0 0 0 5 3 2 4 2
15–19 39 23 32 26 17 137 140 131 94 79
20–24 161 125 115 119 93 396 404 394 379 277
25–29 248 197 226 178 153 552 516 485 450 377
30–34 230 207 232 189 158 525 535 467 466 398
35–39 234 221 210 181 145 540 476 460 433 326
40–44 224 185 163 162 140 419 409 424 379 286
45–49 221 185 171 196 126 423 398 363 326 277
50–54 229 201 201 175 110 378 344 326 323 223
55–59 182 190 168 154 122 304 296 300 274 200
60–64 121 127 102 131 90 187 198 175 191 139
≥65 122 112 106 123 87 123 167 128 159 91
Region of residencea
Northeast 349 315 256 244 184 652 638 554 521 403
Midwest 192 190 199 186 137 488 504 484 476 365
South 1,379 1,205 1,196 1,138 867 2,556 2,507 2,343 2,222 1,703
West 93 64 75 66 51 292 236 275 259 203
Total 2,012 1,774 1,725 1,634 1,240 3,988 3,885 3,656 3,478 2,674
Hispanic/Latinob
Age at diagnosis (yr)
13–14 0 0 0 0 0 1 1 4 3 0
15–19 4 8 7 7 3 31 39 33 34 30
20–24 50 28 29 27 31 100 118 95 111 96
25–29 72 68 60 76 48 137 139 132 145 99
30–34 89 75 88 67 44 159 134 128 144 98
35–39 88 77 87 69 61 126 125 146 114 104
40–44 83 79 72 72 44 122 100 106 112 87
45–49 77 57 77 54 41 102 120 107 96 71
50–54 56 53 62 55 53 99 83 111 94 72
55–59 38 38 48 38 26 68 70 71 63 55
60–64 29 31 20 33 23 40 40 44 50 37
≥65 24 29 31 21 17 40 37 46 38 25
Region of residencea
Northeast 161 140 138 108 78 303 261 244 219 196
Midwest 43 28 35 33 17 58 61 56 69 47
South 306 279 321 296 231 437 458 484 470 359
West 101 96 87 83 64 226 227 238 247 172
Total 611 543 581 520 390 1,024 1,007 1,022 1,004 773
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 1 1 1
20–24 0 0 0 0 0 1 0 0 1 2
25–29 0 1 0 1 0 0 2 0 2 2
30–34 0 1 1 0 1 1 3 2 1 1
35–39 1 0 0 0 1 1 2 0 2 1
40–44 0 0 0 0 0 0 0 0 1 1
45–49 1 1 0 0 0 0 0 0 0 1
50–54 0 0 0 0 0 1 0 1 1 1
55–59 0 0 0 0 0 0 0 1 0 2
60–64 0 0 0 0 0 0 0 0 0 1
≥65 0 1 0 0 0 0 0 0 0 0
Region of residencea
Northeast 0 1 0 0 0 0 1 1 0 1
Midwest 1 0 0 0 0 0 0 0 4 0
South 1 1 1 0 0 0 2 1 1 4
West 0 2 0 1 2 4 4 3 4 7
Total 2 4 2 1 2 4 7 5 9 12
White
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 1 1 0 0
15–19 4 5 4 3 1 30 28 31 31 20
20–24 31 16 20 19 16 103 95 93 91 96
25–29 37 46 48 50 30 132 109 123 130 113
30–34 45 50 61 41 40 140 126 126 125 120
35–39 47 47 51 43 37 108 109 117 121 107
40–44 52 51 42 47 32 94 85 103 97 88
45–49 47 52 54 54 40 102 104 105 103 104
50–54 74 64 44 50 40 101 98 97 95 72
55–59 49 47 50 47 39 92 93 73 82 73
60–64 35 37 38 27 26 53 39 38 46 31
≥65 42 33 32 27 26 20 24 26 23 34
Region of residencea
Northeast 93 81 81 66 62 121 116 105 112 95
Midwest 48 51 57 59 56 161 150 166 174 147
South 255 237 242 215 163 502 489 497 487 435
West 64 77 63 67 44 190 154 164 172 181
Total 461 446 443 407 325 974 910 933 944 858
Multiracial
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 1 1 1 0 12 6 13 10 7
20–24 8 4 3 3 3 39 26 19 22 20
25–29 13 11 9 8 0 26 22 35 35 23
30–34 7 14 15 8 4 28 26 34 22 15
35–39 20 10 6 5 2 33 27 23 19 10
40–44 11 12 4 9 5 17 14 14 21 10
45–49 13 9 7 7 2 27 24 26 20 9
50–54 10 6 9 5 2 13 15 10 15 4
55–59 8 7 1 8 2 18 15 9 5 8
60–64 3 6 4 3 1 6 4 10 7 9
≥65 5 5 4 7 2 9 5 8 6 1
Region of residencea
Northeast 28 23 22 19 4 45 42 42 39 22
Midwest 12 11 6 13 3 45 27 27 31 20
South 52 46 32 27 14 117 89 106 91 65
West 6 7 2 4 3 20 27 26 21 10
Total 99 86 62 64 24 227 184 200 181 116
Total
Age at diagnosis (yr)
13–14 0 0 1 0 0 7 6 7 8 2
15–19 48 37 44 39 22 210 214 210 173 136
20–24 254 175 173 171 143 647 651 608 612 492
25–29 371 327 346 315 234 869 811 790 772 626
30–34 384 352 406 309 249 888 833 774 777 651
35–39 404 369 364 301 249 838 767 759 710 570
40–44 375 330 292 296 223 671 622 662 622 481
45–49 368 311 315 315 212 668 663 611 562 472
50–54 374 327 322 292 209 601 556 555 533 382
55–59 281 285 270 253 193 492 483 466 431 346
60–64 191 206 168 198 142 292 289 273 301 224
≥65 200 183 177 181 136 198 237 214 229 155
Region of residencea
Northeast 639 568 511 451 331 1,155 1,074 972 903 730
Midwest 306 286 300 294 218 765 763 739 774 591
South 2,019 1,782 1,818 1,696 1,289 3,664 3,580 3,467 3,303 2,596
West 286 265 248 229 175 796 715 751 751 619
Total 3,251 2,902 2,877 2,669 2,012 6,380 6,131 5,928 5,730 4,536

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12 should be interpreted with caution. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
Persons whose transmission category is classified as heterosexual contact includes transgender and additional gender identity persons.
Includes persons who have ever had sexual contact with a person known to have, or with a risk factor for, HIV infection (e.g., a person who injects drugs).
Excludes men who have ever had sexual contact with both men and women.

aData are based on residence at time of diagnosis of HIV infection.
bHispanic/Latino persons can be of any race.

Table 7b. Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, sex assigned at birth, race/ethnicity and selected characteristics, 2016–2020—United States and 6 dependent areas
Male sex at birth Female sex at birth
2016 2017 2018 2019 2020 (COVID-19 Pandemic) 2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. No. No. No. No. No. No. No. No. No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 1 0 0 0 0 1 1 0
20–24 0 0 1 2 0 0 3 1 2 0
25–29 0 0 1 0 0 4 5 1 2 1
30–34 1 2 1 1 0 3 2 1 3 6
35–39 1 3 1 0 0 6 4 2 6 6
40–44 1 0 0 2 0 6 3 3 6 5
45–49 1 1 0 0 0 3 5 3 3 2
50–54 1 0 0 1 2 1 5 2 2 1
55–59 0 0 1 1 0 2 2 3 1 2
60–64 0 0 0 0 1 2 2 0 1 1
≥65 1 0 0 0 0 1 0 0 1 1
Region of residencea
Northeast 0 0 1 0 0 1 0 0 0 1
Midwest 1 0 1 2 0 1 3 1 9 4
South 2 3 2 6 2 9 5 8 4 7
West 5 4 3 1 1 15 22 7 12 11
U.S. dependent areas 0 0 0 0 0 0 0 0 0 0
Total 7 7 8 9 3 26 30 15 26 23
Asian
Age at diagnosis (yr)
13–14 0 0 0 0 0 1 0 0 0 0
15–19 0 0 0 1 1 0 2 0 1 1
20–24 3 2 5 1 1 9 5 6 6 2
25–29 2 4 1 2 3 20 18 15 8 11
30–34 11 4 8 3 2 33 8 16 16 12
35–39 13 10 8 2 3 24 24 11 16 15
40–44 4 3 11 5 2 14 11 12 6 4
45–49 8 6 6 4 4 11 12 8 14 8
50–54 4 3 6 6 4 10 12 9 4 9
55–59 3 3 2 5 4 8 7 9 8 6
60–64 4 4 5 4 2 4 6 6 7 7
≥65 6 3 6 3 5 5 5 7 4 4
Region of residencea
Northeast 8 9 13 14 3 32 16 27 13 12
Midwest 9 7 2 1 5 13 18 5 11 8
South 24 12 24 12 12 43 30 28 29 24
West 17 15 19 7 10 49 45 38 37 34
U.S. dependent areas 0 0 0 0 0 0 0 0 0 0
Total 58 42 58 35 30 137 109 97 90 79
Black/African American
Age at diagnosis (yr)
13–14 0 0 0 0 0 5 3 2 4 2
15–19 39 23 32 26 17 137 140 131 94 79
20–24 161 125 115 119 93 396 404 394 379 277
25–29 248 197 227 178 153 552 516 485 450 377
30–34 230 207 232 189 159 525 536 467 466 398
35–39 234 221 210 181 145 540 476 460 433 326
40–44 224 185 163 162 140 419 409 424 379 286
45–49 222 185 172 196 126 423 399 363 326 277
50–54 229 201 201 175 110 378 344 326 323 223
55–59 182 190 169 154 122 304 296 300 274 200
60–64 122 127 102 131 90 187 198 175 191 139
≥65 122 112 106 124 87 123 167 128 159 91
Region of residencea
Northeast 349 315 256 244 184 652 638 554 521 403
Midwest 192 190 199 186 137 488 504 484 476 365
South 1,379 1,205 1,196 1,138 867 2,556 2,507 2,343 2,222 1,703
West 93 64 75 66 51 292 236 275 259 203
U.S. dependent areas 2 0 3 2 1 0 2 0 1 0
Total 2,014 1,774 1,728 1,636 1,241 3,988 3,887 3,656 3,479 2,674
Hispanic/Latinob
Age at diagnosis (yr)
13–14 0 0 0 0 0 1 1 4 3 0
15–19 4 9 8 7 3 33 42 35 34 30
20–24 51 36 31 30 33 105 123 104 115 100
25–29 76 72 68 79 52 142 150 139 151 102
30–34 95 83 97 73 45 167 140 133 153 99
35–39 97 88 92 73 65 141 135 151 118 107
40–44 98 89 75 78 47 136 107 114 125 92
45–49 95 61 81 65 43 116 131 121 104 76
50–54 67 59 77 59 57 106 93 122 99 77
55–59 49 47 51 47 34 82 81 79 75 62
60–64 39 41 24 40 30 46 44 49 55 40
≥65 41 40 40 31 20 42 41 52 46 28
Region of residencea
Northeast 161 140 138 108 78 303 261 244 219 196
Midwest 43 28 35 33 17 58 61 56 69 47
South 306 279 321 296 231 437 458 484 470 359
West 101 96 87 83 64 226 227 238 247 172
U.S. dependent areas 100 83 64 62 38 93 81 80 73 39
Total 711 627 644 581 427 1,117 1,088 1,101 1,077 812
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 0 0 0 0 0 0 1 1 1
20–24 0 1 0 0 0 1 0 0 2 2
25–29 0 1 0 1 0 0 2 0 2 2
30–34 0 1 1 0 1 1 3 2 1 1
35–39 1 0 0 0 1 1 2 0 2 1
40–44 0 0 0 0 0 0 0 0 1 1
45–49 1 1 0 0 0 0 0 0 0 1
50–54 0 0 0 0 0 1 0 1 1 1
55–59 0 0 1 0 0 0 0 1 0 2
60–64 0 0 0 0 0 0 0 0 0 1
≥65 0 1 0 0 0 0 0 0 0 0
Region of residencea
Northeast 0 1 0 0 0 0 1 1 0 1
Midwest 1 0 0 0 0 0 0 0 4 0
South 1 1 1 0 0 0 2 1 1 4
West 0 2 0 1 2 4 4 3 4 7
U.S. dependent areas 0 1 1 0 0 0 0 0 1 0
Total 3 5 2 1 2 4 7 5 10 12
White
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 1 1 0 0
15–19 4 5 4 3 1 30 28 31 31 20
20–24 31 16 20 19 16 103 95 93 91 96
25–29 37 46 48 50 30 132 109 123 130 113
30–34 45 50 61 41 40 140 126 126 125 120
35–39 47 47 51 43 37 108 109 117 121 107
40–44 52 51 42 47 32 94 85 103 97 88
45–49 47 52 54 55 40 102 104 105 103 104
50–54 74 64 44 50 40 101 99 97 95 72
55–59 49 47 50 47 39 92 93 73 82 73
60–64 35 37 38 27 26 53 39 38 46 31
≥65 42 33 32 27 26 20 24 26 23 34
Region of residencea
Northeast 93 81 81 66 62 121 116 105 112 95
Midwest 48 51 57 59 56 161 150 166 174 147
South 255 237 242 215 163 502 489 497 487 435
West 64 77 63 67 44 190 154 164 172 181
U.S. dependent areas 0 0 0 1 0 0 2 0 0 0
Total 461 446 443 408 325 974 911 933 944 858
Multiracial
Age at diagnosis (yr)
13–14 0 0 0 0 0 0 0 0 0 0
15–19 0 1 1 1 0 12 6 13 10 7
20–24 8 4 3 3 3 39 26 19 22 20
25–29 13 11 9 8 0 26 22 35 35 23
30–34 7 14 15 8 4 28 26 34 22 15
35–39 20 11 7 5 2 33 27 23 19 10
40–44 11 12 4 9 5 17 14 14 21 10
45–49 13 9 7 7 2 27 24 26 20 9
50–54 10 6 9 5 2 13 15 10 15 4
55–59 8 7 1 8 2 18 15 9 5 8
60–64 3 6 4 3 1 6 4 10 7 9
≥65 5 5 4 7 2 9 5 8 6 1
Region of residencea
Northeast 28 23 22 19 4 45 42 42 39 22
Midwest 12 11 6 13 3 45 27 27 31 20
South 52 46 32 27 14 117 89 106 91 65
West 6 7 2 4 3 20 27 26 21 10
U.S. dependent areas 0 0 2 0 0 0 0 0 0 0
Total 99 86 64 64 24 227 184 200 181 116
Total
Age at diagnosis (yr)
13–14 0 0 1 0 0 7 6 7 8 2
15–19 48 38 45 39 22 212 218 212 173 136
20–24 255 184 175 174 145 652 656 617 617 496
25–29 375 331 355 318 238 874 822 797 778 629
30–34 390 361 415 315 251 896 840 779 786 652
35–39 413 380 370 305 252 853 777 764 714 573
40–44 390 340 295 303 226 685 629 670 635 486
45–49 387 315 320 327 214 682 675 625 570 477
50–54 385 333 337 296 214 608 567 566 539 387
55–59 292 294 275 262 201 506 494 474 443 353
60–64 203 216 173 205 149 298 293 277 306 227
≥65 217 194 187 192 139 200 241 220 237 158
Region of residencea
Northeast 639 568 511 451 331 1,155 1,074 972 903 730
Midwest 306 286 300 294 218 765 763 739 774 591
South 2,019 1,782 1,818 1,696 1,289 3,664 3,580 3,467 3,303 2,596
West 286 265 248 229 175 796 715 751 751 619
U.S. dependent areas 102 85 70 65 39 93 85 80 75 39
Total 3,353 2,987 2,947 2,734 2,051 6,473 6,216 6,008 5,805 4,575

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12 should be interpreted with caution. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
Persons whose transmission category is classified as heterosexual contact includes transgender and additional gender identity persons.
Includes persons who have ever had sexual contact with a person known to have, or with a risk factor for, HIV infection (e.g., a person who injects drugs).
Excludes men who have ever had sexual contact with both men and women.

aData are based on residence at time of diagnosis of HIV infection.
bHispanic/Latino persons can be of any race.

Table 8a. Diagnoses of HIV infection among persons aged 13–24 years, by age at diagnosis and sex assigned at birth, and selected characteristics, 2020 (COVID-19 Pandemic)—United States
13–14 years 15–17 years 18–19 years 20–22 years 23–24 years Total
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Sex at birth
Male 6 0.1 240 3.8 851 19.8 2,436 36.9 1,828 41.3 5,361 20.6
Female 6 0.1 49 0.8 108 2.6 289 4.6 269 6.3 721 2.9
Race/Ethnicity
American Indian/Alaska Native 0 0.0 2 1.9 3 4.2 14 12.8 14 19.5 33 7.7
Asian 0 0.0 1 0.2 18 4.0 37 5.2 31 5.9 87 3.1
Black/African American 8 0.7 170 10.1 565 48.4 1,506 82.7 1,038 85.3 3,287 46.6
Hispanic/Latinob 4 0.2 71 2.3 223 11.1 678 22.8 553 28.6 1,529 12.6
Native Hawaiian/Other Pacific Islander 0 0.0 0 0.0 4 24.3 4 15.7 4 22.9 12 11.8
White 0 0.0 34 0.5 115 2.6 400 5.8 392 8.4 941 3.5
Multiracial 0 0.0 11 2.3 31 10.5 86 20.1 65 24.5 193 10.6
Transmission categoryc
    Male sex at birthd
Male-to-male sexual contact 5 227 811 2,268 1,653 4,964
Injection drug use 0 1 9 30 31 71
Male-to-male sexual contact and injection drug use 0 4 14 61 73 151
Heterosexual contacte 0 7 15 74 69 165
Perinatalf 1 1 2 2 1 8
Otherg 0 0 0 0 1 1
    Subtotal 6 0.1 240 3.8 851 19.8 2,436 36.9 1,828 41.3 5,361 20.6
    Female sex at birthd
Injection drug use 1 2 8 25 23 59
Heterosexual contacte 2 41 96 253 239 631
Perinatalf 3 6 4 12 6 31
Otherg 0 0 0 0 0 0
    Subtotal 6 0.1 49 0.8 108 2.6 289 4.6 269 6.3 721 2.9
Region of residenceh
Northeast 2 0.2 41 2.0 111 7.7 297 13.8 281 19.9 732 8.8
Midwest 3 0.2 43 1.6 121 6.8 420 15.2 305 17.0 892 8.3
South 5 0.2 163 3.3 590 18.2 1,550 31.2 1,096 33.1 3,404 17.3
West 2 0.1 42 1.4 137 6.9 458 15.0 415 19.3 1,054 8.6
Total 12 0.1 289 2.3 959 11.4 2,725 21.1 2,097 24.2 6,082 11.9

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

aRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
bHispanic/Latino persons can be of any race.
cTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
dData include transgender and additional gender identity persons.
eSexual contact with a person known to have, or with a risk factor for, HIV infection.
fIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
gOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
hData are based on residence at time of diagnosis of HIV infection.

Table 8b. Diagnoses of HIV infection among persons aged 13–24 years, by age at diagnosis and sex assigned at birth, and selected characteristics, 2020 (COVID-19 Pandemic) —United States and 6 dependent areas
13–14 years 15–17 years 18–19 years 20–22 years 23–24 years Total
No. No. No. No. No. No.
Sex at birth
Male 6 242 857 2,448 1,857 5,410
Female 6 49 108 291 271 725
Race/Ethnicity
American Indian/Alaska Native 0 2 3 14 14 33
Asian 0 1 18 37 31 87
Black/African American 8 170 567 1,506 1,038 3,289
Hispanic/Latinoa 4 73 227 692 584 1,580
Native Hawaiian/Other Pacific Islander 0 0 4 4 4 12
White 0 34 115 400 392 941
Multiracial 0 11 31 86 65 193
Transmission categoryb
    Male sex at birthc
Male-to-male sexual contact 5 229 817 2,279 1,679 5,009
Injection drug use 0 1 9 30 32 72
Male-to-male sexual contact and injection drug use 0 4 14 62 73 152
Heterosexual contactd 0 7 15 74 71 167
Perinatale 1 1 2 2 1 8
Otherf 0 0 0 0 1 1
    Subtotal 6 242 857 2,448 1,857 5,410
    Female sex at birthc
Injection drug use 1 2 8 25 23 59
Heterosexual contactd 2 41 96 255 241 635
Perinatale 3 6 4 12 6 31
Otherf 0 0 0 0 0 0
    Subtotal 6 49 108 291 271 725
Region of residenceg
Northeast 2 41 111 297 281 732
Midwest 3 43 121 420 305 892
South 5 163 590 1,550 1,096 3,404
West 2 42 137 458 415 1,054
U.S. dependent areas 0 2 6 14 31 53
Total 12 291 965 2,739 2,128 6,135

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12 should be interpreted with caution.

aHispanic/Latino persons can be of any race.
bTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
cData include transgender and additional gender identity persons.
dSexual contact with a person known to have, or with a risk factor for, HIV infection.
eIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
fOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
gData are based on residence at time of diagnosis of HIV infection..

Table 9a. Diagnoses of HIV infection among children aged <13 years, by year of diagnosis and race/ethnicity, 2016–2020—United States
2016 2017 2018 2019 2020 (COVID-19 Pandemic)
Race/ethnicity No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
American Indian/Alaska Native 0 0.0 0 0.0 0 0.0 1 0.2 1 0.2
Asian 8 0.3 7 0.3 6 0.2 6 0.2 2 0.1
Black/African American 76 1.1 56 0.8 50 0.7 32 0.4 32 0.4
Hispanic/Latinob 18 0.1 16 0.1 11 0.1 7 0.1 9 0.1
Native Hawaiian/other Pacific Islander 0 0.0 1 0.9 0 0.0 0 0.0 1 0.9
White 20 0.1 15 0.1 15 0.1 7 0.0 12 0.0
Multiracial 8 0.3 10 0.4 5 0.2 4 0.2 0 0.0
Total 130 0.2 105 0.2 87 0.2 57 0.1 57 0.1

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

aRates are per 100,000 population.
bHispanic/Latino persons can be of any race.

Table 9b. Diagnoses of HIV infection among children aged <13 years, by year of diagnosis and race/ethnicity, 2016–2020—United States and 6 dependent areas
2016 2017 2018 2019 2020 (COVID-19 Pandemic)
Race/ethnicity No. No. No. No. No.
American Indian/Alaska Native 0 0 0 1 1
Asian 8 7 6 6 2
Black/African American 76 56 50 32 32
Hispanic/Latinoa 18 16 11 7 9
Native Hawaiian/other Pacific Islander 0 1 0 0 1
White 20 15 15 7 12
Multiracial 8 10 5 4 0
Total 130 105 87 57 57

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

aHispanic/Latino persons can be of any race.

Table 10a. Diagnoses of HIV infection among Hispanic/Latino persons aged ≥13 years, by transmission category and place of birth, 2020 (COVID-19 Pandemic) —United States and 6 dependent areas
Caribbeana
United States South Americab Central Americac Mexico Puerto Rico Cuba Other Total
No. % No. % No. % No. % No. % No. % No. % No.d %
Transmission categorye
     Male sex at birthf
Male-to-male sexual contact 2,140 86.8 459 92.2 325 83.2 574 87.0 268 74.6 199 86.5 80.0 73.8 6,359 86.7
Injection drug use 107 4.4 3 0.7 9 2.3 13 2.0 32 8.9 3 1.3 4.0 3.4 280 3.8
Male-to-male sexual contact
and injection drug use
112 4.6 7 1.4 9 2.3 15 2.3 9 2.6 1 0.3 2.0 1.6 261 3.6
Heterosexual contactg 104 4.2 29 5.8 47 12.1 57 8.7 50 13.9 28 12.0 23.0 21.2 427 5.8
    Perinatalh 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0.0 0.0 0 0.0
    Otheri 1 0.0 0 0.0 0 0.1 0 0.1 0 0.0 0 0.0 0.0 0.1 3 0.0
    Subtotal 2,465 100 498 100 391 100 660 100 359 100 230 100 109 100 7,331 100
    Female sex at birthf
Injection drug use 63 19.6 1 3.5 3 3.4 4 8.1 8 11.9 0 1.1 3.0 6.0 136 14.3
Heterosexual contactg 257 80.2 35 95.7 71 96.2 48 88.7 56 88.0 18 97.8 44.0 92.3 812 85.1
Perinatalh 1 0.2 0 0.5 0 0.4 2 3.0 0 0.2 0 0.6 1.0 1.7 5 0.5
Otheri 0 0.0 0 0.3 0 0.0 0 0.2 0 0.0 0 0.6 0.0 0.0 1 0.1
    Subtotal 320 100 37 100 74 100 54 100 64 100 18 100 48 100 954 100
Total 2,785 100 535 100 465 100 714 100 423 100 248 100 157 100 8,285 100

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and percentages based on these numbers, should be interpreted with caution. Hispanic/Latino persons can be of any race.

aCountries include Anguilla, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Haiti, Jamaica, Montserrat, Puerto Rico, Saint Barthelemy, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Turks and Caicos Islands, Virgin Islands (British), and Virgin Islands (U.S).
bCountries include Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Suriname, Uruguay, and Venezuela.
cCountries include Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama.
dTotal includes persons whose place of birth is not among those listed and persons whose place of birth is unknown.
eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
fData include transgender and additional gender identity persons.
gSexual contact with a person known to have, or with a risk factor for, HIV infection.
hIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
iOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.

Table 10b. Diagnoses of HIV infection among transgender and additional gender identity Hispanic/Latino persons ≥13 years, by exposure category and place of birth, 2020 (COVID-19 Pandemic) —United States and 6 dependent areas
Caribbeana
United States South Americab Central Americac Mexico Puerto Rico Cuba Other Total
No. % No. % No. % No. % No. % No. % No. % No.d %
Exposure categorye
    Transgender womanf
Sexual contactg 64 87.7 7 100 23 95.8 25 89.3 6 85.7 5 100 5 100 179 87.7
Injection drug use 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 0.5
Sexual contactg
and injection drug use
7 9.6 0 0.0 0 0.0 2 7.1 0 0.0 0 0.0 0 0.0 13 6.4
    Otherh 2 2.7 0 0.0 1 4.2 1 3.6 1 14.3 0 0.0 0 0.0 11 5.4
    Subtotal 73 100 7 100 24 100 28 100 7 100 5 100 5 100 204 100
    Transgender manf
Sexual contactg 5 55.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 6 60.0
Injection drug use 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Sexual contactg
and injection drug use
4 44.4 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 4 40.0
    Otherh 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
    Subtotal 9 100 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 10 100
Additional gender identityi 0.0 0.0 0.0 0.0 0.0
Sexual contactg 3 100 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 3 75.0
Injection drug use 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Sexual contactg
and injection drug use
0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
    Otherh 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 1 25.0
     Subtotal 3 100 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 4 100
Total 85 100 7 100 24 100 28 100 7 100 5 100 5 100 218 100

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and percentages based on these numbers, should be interpreted with caution. Hispanic/Latino persons can be of any race.

aCountries include Anguilla, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Haiti, Jamaica, Montserrat, Puerto Rico, Saint Barthelemy, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Turks and Caicos Islands, Virgin Islands (British), and Virgin Islands (U.S).
bCountries include Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Suriname, Uruguay, and Venezuela.
cCountries include Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama.
dTotal includes persons whose place of birth is not among those listed and persons whose place of birth is unknown.
eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
fData include transgender and additional gender identity persons.
gSexual contact with a person known to have, or with a risk factor for, HIV infection.
hIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
iOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.

Table 11a. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2016–2020—United States
2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Gender
Male 12,224 12,244 12,103 12,252 13,530
Female 4,025 3,995 3,984 3,830 4,437
Transgender woman/girlb 120 106 117 144 188
Transgender man/boyb 2 5 5 5 9
Additional gender identityc 1 2 1 1 0
Age at death (yr)
<13 1 0.0 2 0.0 1 0.0 2 0.0 4 0.0
13–14 1 0.0 0 0.0 0 0.0 1 0.0 0 0.0
15–19 10 0.0 7 0.0 9 0.0 10 0.0 14 0.1
20–24 155 0.7 144 0.7 121 0.6 122 0.6 131 0.6
25–29 444 1.9 445 1.9 419 1.8 433 1.8 428 1.8
30–34 656 3.0 601 2.7 614 2.8 662 2.9 754 3.3
35–39 838 4.0 864 4.1 813 3.8 855 3.9 889 4.1
40–44 1,130 5.7 970 5.0 958 4.9 932 4.7 1,078 5.3
45–49 1,812 8.7 1,743 8.3 1,599 7.7 1,394 6.8 1,410 7.1
50–54 2,838 13.0 2,726 12.8 2,583 12.4 2,231 10.9 2,225 10.9
55–59 2,985 13.6 2,971 13.5 2,930 13.4 2,909 13.3 3,166 14.7
60–64 2,413 12.4 2,489 12.5 2,526 12.4 2,664 13.0 3,029 14.6
≥65 3,089 6.3 3,390 6.7 3,637 6.9 4,017 7.4 5,036 9.0
Race/ethnicity
American Indian/Alaska Native 47 2.0 47 2.0 48 2.0 58 2.4 78 3.2
Asiand 100 0.6 88 0.5 84 0.4 101 0.5 97 0.5
Black/African American 7,233 18.0 7,199 17.7 6,984 17.1 6,993 17.0 7,930 19.1
Hispanic/Latinoe 2,632 4.6 2,694 4.6 2,840 4.8 2,741 4.5 3,245 5.3
Native Hawaiian/other Pacific Islander 14 2.5 9 1.5 13 2.2 14 2.3 10 1.6
White 5,310 2.7 5,239 2.6 5,151 2.6 5,234 2.7 5,514 2.8
Multiracial 1,033 15.2 1,074 15.3 1,090 15.2 1,087 14.7 1,290 17.1
Transmission categoryf
     Male sex at birth (≥13 yrs at death)g
     Male-to-male sexual contact 6,889 6,992 6,893 7,177 7,801
     Injection drug use 2,270 2,170 2,173 2,071 2,327
 Male-to-male sexual contact
and injection drug use
1,391 1,372 1,444 1,366 1,595
     Heterosexual contacth 1,690 1,709 1,602 1,685 1,873
     Perinatali 40 41 52 42 56
     Otherj 63 67 57 55 64
     Subtotal 12,344 9.3 12,351 9.3 12,220 9.1 12,395 9.2 13,716 10.1
     Female sex at birth (≥13 yrs at death)g
     Injection drug use 1,390 1,381 1,323 1,304 1,425
     Heterosexual contacth 2,562 2,547 2,603 2,469 2,939
     Perinatali 49 43 36 37 44
     Otherj 26 28 27 26 37
     Subtotal 4,027 2.9 3,999 2.9 3,989 2.8 3,835 2.7 4,444 3.1
     Child (<13 yrs at death)
     Perinatal 1 2 1 1 3
     Otherj 0 0 0 1 1
     Subtotal 1 0.0 2 0.0 1 0.0 2 0.0 4 0.0
Region of residencek
Northeast 3,709 6.6 3,699 6.6 3,529 6.3 3,632 6.5 4,426 7.9
Midwest 1,858 2.7 1,916 2.8 2,004 2.9 1,939 2.8 2,230 3.3
South 8,049 6.6 7,997 6.5 7,870 6.3 7,894 6.3 8,608 6.8
West 2,756 3.6 2,740 3.5 2,807 3.6 2,767 3.5 2,900 3.7
Totall 16,372 5.1 16,352 5.0 16,210 5.0 16,232 4.9 18,164 5.5

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

aRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
bTransgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
dIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
eHispanic/Latino persons can be of any race.
fTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
gData include transgender and additional gender identity persons.
hSexual contact with a person known to have, or with a risk factor for, HIV infection.
iIncludes individuals aged ≥13 years at time of diagnosis of HIV infection.
jOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
kData are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
lIncludes persons whose race/ethnicity is unknown.

Table 11b. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2016–2020—United States and 6 dependent areas
2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Gender
Male 12,549 12,545 12,395 12,526 13,776
Female 4,121 4,103 4,060 3,913 4,519
Transgender woman/girlb 120 108 118 146 189
Transgender man/boyb 2 5 5 5 9
Additional gender identityc 1 2 1 1 0
Age at death (yr)
<13 1 0.0 2 0.0 1 0.0 2 0.0 4 0.0
13–14 1 0.0 0 0.0 0 0.0 1 0.0 0 0.0
15–19 11 0.1 7 0.0 9 0.0 10 0.0 14 0.1
20–24 159 0.7 146 0.7 125 0.6 124 0.6 131 0.6
25–29 451 1.9 451 1.9 427 1.8 439 1.8 430 1.8
30–34 664 3.0 616 2.8 626 2.8 674 3.0 758 3.3
35–39 870 4.1 879 4.1 832 3.8 872 4.0 908 4.1
40–44 1,161 5.8 1,005 5.1 988 5.0 970 4.8 1,107 5.4
45–49 1,864 8.8 1,795 8.5 1,637 7.8 1,431 6.9 1,441 7.1
50–54 2,910 13.2 2,803 13.0 2,634 12.5 2,305 11.1 2,265 11.0
55–59 3,060 13.8 3,053 13.8 3,001 13.5 2,961 13.4 3,235 14.8
60–64 2,468 12.5 2,531 12.6 2,575 12.5 2,716 13.1 3,076 14.6
≥65 3,173 6.4 3,475 6.8 3,724 7.0 4,086 7.5 5,124 9.1
Race/ethnicity
American Indian/Alaska Native 47 47 48 58 78
Asiand 100 88 84 101 97
Black/African American 7,243 7,204 6,984 6,994 7,932
Hispanic/Latinoe 3,039 3,099 3,203 3,092 3,570
Native Hawaiian/other Pacific Islander 16 9 16 16 10
White 5,311 5,240 5,152 5,236 5,516
Multiracial 1,034 1,074 1,092 1,090 1,290
Transmission categoryf
Male sex at birth (≥13 yrs at death)g
     Male-to-male sexual contact 6,968 7,063 6,972 7,250 7,874
     Injection drug use 2,403 2,302 2,295 2,191 2,424
 Male-to-male sexual contact
and injection drug use
1,423 1,396 1,467 1,390 1,621
    Heterosexual contacth 1,766 1,783 1,664 1,742 1,923
    Perinatali 46 42 58 44 57
    Otherj 63 67 58 55 64
     Subtotal 12,669 9.5 12,654 9.4 12,513 9.2 12,671 9.3 13,963 10.2
Female sex at birth (≥13 yrs at death)g
     Injection drug use 1,425 1,416 1,356 1,335 1,450
     Heterosexual contacth 2,620 2,619 2,644 2,519 2,995
     Perinatali 51 44 38 38 44
     Otherj 27 29 27 27 37
     Subtotal 4,123 2.9 4,107 2.9 4,065 2.9 3,918 2.7 4,526 3.2
     Child (<13 yrs at death)
     Perinatal 1 2 1 1 3
     Otherj 0 0 0 1 1
     Subtotal 1 0.0 2 0.0 1 0.0 2 0.0 4 0.0
Region of residencek
Northeast 3,709 6.6 3,699 6.6 3,529 6.3 3,632 6.5 4,426 7.9
Midwest 1,858 2.7 1,916 2.8 2,004 2.9 1,939 2.8 2,230 3.3
South 8,049 6.6 7,997 6.5 7,870 6.3 7,894 6.3 8,608 6.8
West 2,756 3.6 2,740 3.5 2,807 3.6 2,767 3.5 2,900 3.7
U.S. dependent areas 421 11.1 411 11.0 369 10.3 359 10.0 329 9.3
Totall 16,793 5.1 16,763 5.1 16,579 5.0 16,591 5.0 18,493 5.6

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

aRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.
bTransgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
dIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
eHispanic/Latino persons can be of any race.
fTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
gData include transgender and additional gender identity persons.
hSexual contact with a person known to have, or with a risk factor for, HIV infection.
iIncludes individuals aged ≥13 years at time of diagnosis of HIV infection.
jOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
kData are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
lIncludes persons whose race/ethnicity is unknown.

Table 12a. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID-19 Pandemic)—United States
American Indian/Alaska Native Asiana Black/African American Hispanic/Latinob Native Hawaiian/other Pacific Islander White Multiracial Totalc
No. Rated No. Rated No. Rated No. Rated No. Rated No. Rated No. Rated No. Rated
Gender
Male 41 79 5,331 2,497 8 4,672 902 13,530
Female 33 15 2,502 697 1 820 369 4,437
Transgender woman/girle 4 3 94 49 1 20 17 188
Transgender man/boye 0 0 3 2 0 2 2 9
Additional gender identityf 0 0 0 0 0 0 0 0
Age at death (yr)
<13 0 0.0 0 0.0 2 0.0 0 0.0 0 0.0 2 0.0 0 0.0 4 0.0
13–14 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
15–19 0 0.0 0 0.0 7 0.2 2 0.0 0 0.0 4 0.0 1 0.1 14 0.1
20–24 0 0.0 3 0.2 76 2.5 27 0.6 0 0.0 18 0.2 7 1.0 131 0.6
25–29 2 1.0 5 0.3 210 6.1 92 1.9 0 0.0 89 0.7 30 4.9 428 1.8
30–34 8 4.4 2 0.1 367 11.6 142 3.0 2 3.7 182 1.4 51 10.9 754 3.3
35–39 7 4.4 9 0.6 407 14.6 167 3.7 1 2.0 238 1.9 60 15.6 889 4.1
40–44 4 2.7 8 0.5 515 19.8 216 5.1 2 4.7 257 2.2 76 23.4 1,078 5.3
45–49 9 6.4 7 0.5 642 25.5 280 7.2 0 0.0 365 3.1 107 38.6 1,410 7.1
50–54 11 7.7 14 1.1 886 35.2 443 13.1 2 5.6 717 5.6 152 62.2 2,225 10.9
55–59 11 7.1 12 1.1 1,280 49.3 548 18.7 1 2.9 1,053 7.2 261 111.1 3,166 14.7
60–64 9 6.2 16 1.6 1,370 57.3 486 20.9 1 3.3 927 6.3 220 104.4 3,029 14.6
≥65 17 5.4 21 0.8 2,168 41.8 842 17.2 1 1.6 1,662 3.9 325 71.6 5,036 9.0
Transmission categoryg
    Male sex at birth (≥13 yrs at death)h
Male-to-male sexual contact 30 60 2,516 1,404 6 3,289 498 7,801
Injection drug use 7 4 1,154 525 0 472 164 2,327
Male-to-male sexual contact
and injection drug use
5 6 448 315 1 660 160 1,595
Heterosexual contacti 3 12 1,256 281 2 232 88 1,873
Perinatalj 0 0 33 13 0 4 6 56
Otherk 0 1 18 9 0 34 3 64
Subtotal 45 4.6 82 1.1 5,424 33.5 2,546 10.6 9 3.6 4,691 5.6 919 37.6 13,716 10.1
Female sex at birth (≥13 yrs at death)h
Injection drug use 14 3 643 263 0 379 123 1,425
Heterosexual contacti 19 12 1,820 423 1 427 238 2,939
Perinatalj 0 0 29 8 0 1 6 44
     Otherk 0 1 13 6 0 14 4 37
     Subtotal 33 3.2 15 0.2 2,504 13.8 699 2.9 1 0.4 821 0.9 371 14.4 4,444 3.1
     Child (<13 yrs at death)
     Perinatal 0 0 2 0 0 1 0 3
     Otherk 0 0 0 0 0 1 0 1
     Subtotal 0 0.0 0 0.0 2 0.0 0 0.0 0 0.0 2 0.0 0 0.0 4 0.0
Region of residencel
Northeast 0 0.0 21 0.5 1,763 27.8 1,313 15.6 0 0.0 909 2.5 420 41.5 4,426 7.9
Midwest 8 1.9 11 0.5 969 13.4 182 3.2 0 0.0 890 1.7 170 11.8 2,230 3.3
South 27 3.3 17 0.4 4,699 19.4 1,007 4.3 2 2.0 2,351 3.3 505 19.9 8,608 6.8
West 43 4.0 48 0.6 499 13.7 743 3.1 8 1.8 1,364 3.5 195 7.6 2,900 3.7
Total 78 3.2 97 0.5 7,930 19.1 3,245 5.3 10 1.6 5,514 2.8 1,290 17.1 18,164 5.5

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

aIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
bHispanic/Latino persons can be of any race.
cIncludes persons whose race/ethnicity is unknown.
dRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
e“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
fAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
gTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
hData include transgender and additional gender identity persons.
iSexual contact with a person known to have, or with a risk factor for, HIV infection.
jIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
kOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
lData are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.

Table 12b. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID-19 Pandemic)—United States and 6 dependent areas
American Indian/Alaska Native Asiana Black/African American Hispanic/Latinob Native Hawaiian/other Pacific Islander White Multiracial Totalc
No. No. No. No. No. No. No. No.
Gender
Male 41 79 5,332 2,740 8 4,674 902 13,776
Female 33 15 2,503 778 1 820 369 4,519
Transgender woman/girld 4 3 94 50 1 20 17 189
Transgender man/boyd 0 0 3 2 0 2 2 9
Additional gender identitye 0 0 0 0 0 0 0 0
Age at death (yr)
<13 0 0 2 0 0 2 0 4
13–14 0 0 0 0 0 0 0 0
15–19 0 0 7 2 0 4 1 14
20–24 0 3 76 27 0 18 7 131
25–29 2 5 210 94 0 89 30 430
30–34 8 2 367 146 2 182 51 758
35–39 7 9 407 186 1 238 60 908
40–44 4 8 515 245 2 257 76 1,107
45–49 9 7 642 311 0 365 107 1,441
50–54 11 14 886 482 2 718 152 2,265
55–59 11 12 1,281 616 1 1,053 261 3,235
60–64 9 16 1,370 533 1 927 220 3,076
≥65 17 21 2,169 928 1 1,663 325 5,124
Transmission categoryf
    Male sex at birth (≥13 yrs at death)g
Male-to-male sexual contact 30 60 2,516 1,475 6 3,290 498 7,874
     Injection drug use 7 4 1,154 622 0 472 164 2,424
Male-to-male sexual contact and injection drug use 5 6 448 341 1 661 160 1,621
Heterosexual contacth 3 12 1,257 329 2 232 88 1,922
Perinatali 0 0 33 14 0 4 6 57
     Otherj 0 1 18 9 0 34 3 64
     Subtotal 45 82 5,425 2,790 9 4,693 919 13,963
Female sex at birth (≥13 yrs at death)g
     Injection drug use 14 3 643 288 0 379 123 1,450
     Heterosexual contacth 19 12 1,821 478 1 427 238 2,995
 Perinatali 0 0 29 8 0 1 6 44
     Otherj 0 1 13 6 0 14 4 37
     Subtotal 33 15 2,505 780 1 821 371 4,526
     Child (<13 yrs at death)
     Perinatal 0 0 2 0 0 1 0 3
     Otherj 0 0 0 0 0 1 0 1
     Subtotal 0 0 2 0 0 2 0 4
Region of residencek
Northeast 0 21 1,763 1,313 0 909 420 4,426
Midwest 8 11 969 182 0 890 170 2,230
South 27 17 4,699 1,007 2 2,351 505 8,608
West 43 48 499 743 8 1,364 195 2,900
U.S. dependent areas 0 0 2 325 0 2 0 329
Total 78 97 7,932 3,570 10 5,516 1,290 18,493

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, should be interpreted with caution.

aIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
bHispanic/Latino persons can be of any race.
cIncludes persons whose race/ethnicity is unknown.
d“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
eAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
fTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
gData include transgender and additional gender identity persons.
hSexual contact with a person known to have, or with a risk factor for, HIV infection.
iIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
jOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
kData are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.

 Table 13a. Deaths of persons aged ≥13 years with diagnosed HIV infection, by year of death, sex assigned at birth, and selected characteristics, 2016–2020—United States
2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Male sex at birthb
Age at death (yr)
13–14 1 0.0 0 0.0 0 0.0 1 0.0 0 0.0
15–19 5 0.0 5 0.0 5 0.0 8 0.1 10 0.1
20–24 111 1.0 112 1.0 95 0.9 94 0.8 101 0.9
25–29 350 3.0 347 2.9 346 2.9 368 3.1 334 2.8
30–34 474 4.3 446 4.0 464 4.1 510 4.5 571 4.9
35–39 584 5.6 625 5.9 576 5.3 617 5.7 654 6.0
40–44 743 7.6 659 6.8 631 6.5 642 6.5 762 7.5
45–49 1,303 12.6 1,226 11.8 1,127 11.0 976 9.7 971 9.8
50–54 2,125 19.8 2,035 19.4 1,904 18.6 1,651 16.4 1,651 16.4
55–59 2,327 21.8 2,249 21.1 2,255 21.2 2,266 21.3 2,444 23.2
60–64 1,844 19.8 1,933 20.3 1,909 19.6 2,056 20.9 2,322 23.3
≥65 2,477 11.4 2,714 12.1 2,908 12.5 3,206 13.3 3,896 15.7
Race/ethnicity
American Indian/Alaska Native 38 4.0 33 3.4 33 3.4 39 4.0 45 4.6
Asianc 87 1.2 73 1.0 73 1.0 93 1.2 82 1.1
Black/African American 4,855 31.2 4,909 31.2 4,708 29.6 4,791 29.9 5,424 33.5
Hispanic/Latinod 2,033 9.2 2,109 9.3 2,257 9.7 2,174 9.2 2,546 10.6
Native Hawaiian/other Pacific Islander 10 4.3 5 2.1 12 5.0 9 3.6 9 3.6
White 4,552 5.4 4,413 5.2 4,320 5.1 4,464 5.3 4,691 5.6
Multiracial 766 36.0 808 36.7 817 35.8 822 34.8 919 37.6
Transmission categorye
Male-to-male sexual contact 6,889 6,992 6,893 7,177 7,801
Injection drug use 2,270 2,170 2,173 2,071 2,327
Male-to-male sexual contact
and injection drug use
1,391 1,372 1,444 1,366 1,595
Heterosexual contactf 1,690 1,709 1,602 1,685 1,873
Perinatalg 40 41 52 42 56
Otherh 63 67 57 55 64
Region of residencei
Northeast 2,628 11.4 2,623 11.4 2,490 10.8 2,586 11.2 3,151 13.6
Midwest 1,475 5.3 1,513 5.4 1,598 5.7 1,554 5.5 1,795 6.4
South 5,838 11.8 5,820 11.6 5,707 11.3 5,861 11.5 6,252 12.1
West 2,403 7.6 2,395 7.5 2,425 7.5 2,394 7.4 2,518 7.7
Subtotal 12,344 9.3 12,351 9.3 12,220 9.1 12,395 9.2 13,716 10.1
Female sex at birthb
Age at death (yr)
13–14 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
15–19 5 0.0 2 0.0 4 0.0 2 0.0 4 0.0
20–24 44 0.4 32 0.3 26 0.2 28 0.3 30 0.3
25–29 94 0.8 98 0.9 73 0.6 65 0.6 94 0.8
30–34 182 1.7 155 1.4 150 1.4 152 1.4 183 1.6
35–39 254 2.4 239 2.3 237 2.2 238 2.2 235 2.2
40–44 387 3.9 311 3.2 327 3.3 290 2.9 316 3.1
45–49 509 4.8 517 4.9 472 4.5 418 4.1 439 4.3
50–54 713 6.4 691 6.4 679 6.4 580 5.6 574 5.5
55–59 658 5.8 722 6.4 675 6.0 643 5.7 722 6.5
60–64 569 5.6 556 5.3 617 5.8 608 5.7 707 6.5
≥65 612 2.2 676 2.4 729 2.5 811 2.7 1,140 3.7
Race/ethnicity
American Indian/Alaska Native 9 0.9 14 1.4 15 1.5 19 1.9 33 3.2
Asianc 13 0.2 15 0.2 11 0.1 8 0.1 15 0.2
Black/African American 2,377 13.6 2,289 13.0 2,275 12.8 2,201 12.3 2,504 13.8
Hispanic/Latinod 599 2.7 585 2.6 583 2.6 566 2.4 699 2.9
Native Hawaiian/other Pacific Islander 4 1.7 4 1.7 1 0.4 5 2.0 1 0.4
White 758 0.9 825 0.9 831 1.0 770 0.9 821 0.9
Multiracial 267 11.8 266 11.3 273 11.3 265 10.6 371 14.4
Transmission categorye
   Injection drug use 1,390 1,381 1,323 1,304 1,425
   Heterosexual contactf 2,562 2,547 2,603 2,469 2,939
   Perinatalg 49 43 36 37 44
   Otherh 26 28 27 26 37
Region of residencei
Northeast 1,081 4.4 1,076 4.4 1,038 4.2 1,046 4.2 1,273 5.2
Midwest 382 1.3 402 1.4 406 1.4 384 1.3 435 1.5
South 2,211 4.2 2,176 4.1 2,163 4.0 2,032 3.8 2,355 4.3
West 353 1.1 345 1.1 382 1.2 373 1.1 381 1.1
Subtotal 4,027 2.9 3,999 2.9 3,989 2.8 3,835 2.7 4,444 3.1
Total 16,371 6.1 16,350 6.0 16,209 5.9 16,230 5.9 18,160 6.5

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

aRates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
bData include transgender and additional gender identity persons.
cIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
dHispanic/Latino persons can be of any race.
eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
fSexual contact with a person known to have, or with a risk factor for, HIV infection.
gIncludes individuals aged ≥13 years at time of diagnosis of HIV infection.
hOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
iData are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.

Table 13b. Deaths of persons aged ≥13 years with diagnosed HIV infection, by year of death, sex assigned at birth, and selected characteristics, 2016–2020—United States and 6 dependent areas
2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Male sex at birthb
Age at death (yr)
13–14 1 0.0 0 0.0 0 0.0 1 0.0 0 0.0
15–19 6 0.1 5 0.0 5 0.0 8 0.1 10 0.1
20–24 114 1.0 113 1.0 99 0.9 96 0.9 101 0.9
25–29 356 3.0 351 2.9 353 2.9 372 3.1 336 2.8
30–34 479 4.3 456 4.1 472 4.2 516 4.5 573 4.9
35–39 609 5.8 636 5.9 589 5.4 628 5.7 669 6.1
40–44 763 7.7 687 7.0 655 6.6 669 6.7 786 7.7
45–49 1,346 12.9 1,267 12.1 1,154 11.1 1,003 9.8 989 9.9
50–54 2,181 20.1 2,094 19.7 1,942 18.7 1,711 16.8 1,681 16.5
55–59 2,384 22.1 2,307 21.4 2,311 21.5 2,306 21.4 2,495 23.5
60–64 1,889 20.1 1,962 20.4 1,951 19.9 2,097 21.1 2,356 23.4
≥65 2,541 11.5 2,776 12.2 2,982 12.6 3,264 13.4 3,967 15.8
Race/ethnicity
American Indian/Alaska Native 38 33 33 39 45
Asianc 87 73 73 93 82
Black/African American 4,862 4,913 4,708 4,792 5,425
Hispanic/Latinod 2,349 2,407 2,546 2,443 2,790
Native Hawaiian/other Pacific Islander 11 5 13 11 9
White 4,552 4,414 4,321 4,466 4,693
Multiracial 767 808 819 824 919
Transmission categorye
 Male-to-male sexual contact 6,968 7,063 6,972 7,249 7,874
 Injection drug use 2,403 2,302 2,295 2,191 2,424
 Male-to-male sexual contact
and injection drug use
1,423 1,396 1,467 1,390 1,621
 Heterosexual contactf 1,766 1,783 1,664 1,742 1,923
 Perinatalg 46 42 58 44 57
 Otherh 63 67 58 55 64
Region of residencei
Northeast 2,628 11.4 2,623 11.4 2,490 10.8 2,586 11.2 3,151 13.6
Midwest 1,475 5.3 1,513 5.4 1,598 5.7 1,554 5.5 1,795 6.4
South 5,838 11.8 5,820 11.6 5,707 11.3 5,861 11.5 6,252 12.1
West 2,403 7.6 2,395 7.5 2,425 7.5 2,394 7.4 2,518 7.7
US dependent areas 325 21.2 303 20.0 293 19.9 276 18.7 247 16.8
Subtotal 12,669 9.5 12,654 9.4 12,513 9.2 12,671 9.3 13,963 10.2
Female sex at birthb
Age at death (yr)
13–14 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
15–19 5 0.0 2 0.0 4 0.0 2 0.0 4 0.0
20–24 45 0.4 33 0.3 26 0.2 28 0.3 30 0.3
25–29 95 0.8 100 0.9 74 0.6 67 0.6 94 0.8
30–34 185 1.7 160 1.5 154 1.4 158 1.4 185 1.6
35–39 261 2.5 243 2.3 243 2.2 244 2.2 239 2.2
40–44 398 4.0 318 3.2 333 3.3 301 3.0 321 3.1
45–49 518 4.9 528 4.9 483 4.6 428 4.1 452 4.4
50–54 729 6.5 709 6.5 692 6.5 594 5.6 584 5.6
55–59 676 5.9 746 6.5 690 6.1 655 5.8 740 6.6
60–64 579 5.6 569 5.4 624 5.8 619 5.7 720 6.6
≥65 632 2.3 699 2.4 742 2.5 822 2.7 1,157 3.7
Race/ethnicity
American Indian/Alaska Native 9 14 15 19 33
Asianc 13 15 11 8 15
Black/African American 2,380 2,290 2,275 2,201 2,505
Hispanic/Latinod 690 692 657 648 780
Native Hawaiian/other Pacific Islander 5 4 3 5 1
White 759 825 831 770 821
Multiracial 267 266 273 266 371
Transmission categorye
Injection drug use 1,425 1,416 1,356 1,335 1,450
Heterosexual contactf 2,620 2,619 2,644 2,519 2,995
Perinatalg 51 44 38 38 44
Otherh 27 29 27 27 37
Region of residencei
Northeast 1,081 4.4 1,076 4.4 1,038 4.2 1,046 4.2 1,273 5.2
Midwest 382 1.3 402 1.4 406 1.4 384 1.3 435 1.5
South 2,211 4.2 2,176 4.1 2,163 4.0 2,032 3.8 2,355 4.3
West 353 1.1 345 1.1 382 1.2 373 1.1 381 1.1
US dependent areas 96 5.6 108 6.4 76 4.6 83 5.0 82 5.0
Subtotal 4,123 2.9 4,107 2.9 4,065 2.9 3,918 2.7 4,526 3.2
Total 16,792 6.1 16,761 6.1 16,578 6.0 16,589 5.9 18,489 6.6

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

aRates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.
bData include transgender and additional gender identity persons.
cIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
dHispanic/Latino persons can be of any race.
eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
fSexual contact with a person known to have, or with a risk factor for, HIV infection.
gIncludes individuals aged ≥13 years at time of diagnosis of HIV infection.
hOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
iData are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.

Table 14a. Deaths of transgender and additional gender identity persons aged ≥13 years with diagnosed HIV infection, by year of death and selected characteristics, 2016–2020—United States
2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. No. No. No. No.
Transgender womana
Age at death (yr)
13–14 0 0 0 0 0
15–19 0 0 0 0 0
20–24 1 2 1 5 7
25–29 10 8 12 17 15
30–34 10 9 9 19 26
35–39 13 15 13 16 26
40–44 12 13 12 17 21
45–49 21 18 12 17 25
50–54 13 10 19 17 19
55–59 17 18 17 17 24
60–64 11 7 11 12 12
≥65 12 6 11 7 13
Race/ethnicity
American Indian/Alaska Native 0 0 2 1 4
Asianb 3 0 2 1 3
Black/African American 55 43 45 69 94
Hispanic/Latinoc 27 36 34 33 49
Native Hawaiian/other Pacific Islander 1 1 0 0 1
White 22 18 21 23 20
Multiracial 12 8 13 17 17
Exposure categoryd
   Sexual contacte 83 77 77 98 128
Injection drug use 0 0 0 1 2
Sexual contacte
and injection drug use
33 26 38 39 53
Otherf 4 3 2 6 5
Region of residenceg
Northeast 27 25 32 39 58
Midwest 12 11 11 22 22
South 41 39 42 54 63
West 40 31 32 29 45
Subtotal 120 106 117 144 188
Transgender mana
Age at death (yr)
13–14 0 0 0 0 0
15–19 0 0 0 0 0
20–24 0 0 0 0 1
25–29 0 0 0 1 0
30–34 0 1 0 0 1
35–39 2 0 0 0 1
40–44 0 0 0 0 2
45–49 0 1 2 0 1
50–54 0 0 1 1 0
55–59 0 2 1 1 1
60–64 0 0 0 2 1
≥65 0 1 1 0 1
Race/ethnicity
American Indian/Alaska Native 0 0 0 0 0
Asianb 0 0 0 0 0
Black/African American 1 3 0 1 3
Hispanic/Latinoc 0 1 2 2 2
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 1 0 2 1 2
Multiracial 0 1 1 1 2
Exposure categoryd
    Sexual contacte 2 3 0 3 6
Injection drug use 0 0 0 0 0
Sexual contacte
and injection drug use
0 2 5 1 3
 Otherf 0 0 0 1 0
Region of residenceg
Northeast 0 1 0 1 2
Midwest 0 0 1 1 2
South 2 3 3 3 3
West 0 1 1 0 2
Subtotal 2 5 5 5 9
Additional gender identityh
Age at death (yr)
13–14 0 0 0 0 0
15–19 0 0 0 0 0
20–24 0 0 0 0 0
25–29 0 0 0 0 0
30–34 1 1 0 0 0
35–39 0 0 0 0 0
40–44 0 0 0 1 0
45–49 0 0 0 0 0
50–54 0 0 0 0 0
55–59 0 1 1 0 0
60–64 0 0 0 0 0
≥65 0 0 0 0 0
Race/ethnicity
 American Indian/Alaska Native 0 0 0 0 0
 Asianb 0 0 0 0 0
 Black/African American 1 0 0 1 0
 Hispanic/Latinoc 0 1 1 0 0
 Native Hawaiian/other Pacific Islander 0 0 0 0 0
 White 0 1 0 0 0
 Multiracial 0 0 0 0 0
 Exposure categoryd
 Sexual contacte 1 1 0 1 0
  Injection drug use 0 0 0 0 0
Sexual contacte
and injection drug use
0 1 1 0 0
     Otherf 0 0 0 0 0
Region of residenceg
Northeast 0 1 0 1 0
Midwest 0 1 0 0 0
South 0 0 0 0 0
West 1 0 1 0 0
Subtotal 1 2 1 1 0
Total 123 113 123 150 197

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Additional gender identity not included due to small numbers.

a“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
bIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
cHispanic/Latino persons can be of any race.
dClassification of adults and adolescents based on their risk factors that may have been responsible for HIV transmission; classification has no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. The categories are mutually exclusive. Data were not statistically adjusted to account for missing exposure category.
eFor persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
fOther risk factors including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
gData are based on residence at the time of death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
hAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 14b. Deaths of transgender and additional gender identity persons aged ≥13 years with diagnosed HIV infection, by year of death and selected characteristics, 2016–2020—United States and 6 dependent areas
2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. No. No. No. No.
Transgender womana
Age at death (yr)
13–14 0 0 0 0 0
15–19 0 0 0 0 0
20–24 1 2 1 5 7
25–29 10 8 12 17 15
30–34 10 9 9 19 26
35–39 13 16 13 16 26
40–44 12 13 12 17 21
45–49 21 18 12 18 25
50–54 13 11 19 17 20
55–59 17 18 17 17 24
60–64 11 7 11 12 12
≥65 12 6 12 8 13
Race/ethnicity
American Indian/Alaska Native 0 0 2 1 4
Asianb 3 0 2 1 3
Black/African American 55 43 45 69 94
Hispanic/Latinoc 27 38 35 35 50
Native Hawaiian/other Pacific Islander 1 1 0 0 1
White 22 18 21 23 20
Multiracial 12 8 13 17 17
Exposure categoryd
    Sexual contacte 83 77 78 98 129
    Injection drug use 0 0 0 1 2
Sexual contacte
and injection drug use
33 28 38 41 53
     Otherf 4 3 2 6 5
Region of residenceg
Northeast 27 25 32 39 58
Midwest 12 11 11 22 22
South 41 39 42 54 63
West 40 31 32 29 45
US dependent areas 0 2 1 2 1
Subtotal 120 108 118 146 189
Transgender mana
Age at death (yr)
13–14 0 0 0 0 0
15–19 0 0 0 0 0
20–24 0 0 0 0 1
25–29 0 0 0 1 0
30–34 0 1 0 0 1
35–39 2 0 0 0 1
40–44 0 0 0 0 2
45–49 0 1 2 0 1
50–54 0 0 1 1 0
55–59 0 2 1 1 1
60–64 0 0 0 2 1
≥65 0 1 1 0 1
Race/ethnicity
American Indian/Alaska Native 0 0 0 0 0
Asianb 0 0 0 0 0
Black/African American 1 3 0 1 3
Hispanic/Latinoc 0 1 2 2 2
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 1 0 2 1 2
Multiracial 0 1 1 1 2
Exposure categoryd
    Sexual contacte 2 3 0 3 6
    Injection drug use 0 0 0 0 0
Sexual contacte
and injection drug use
0 2 5 1 3
     Otherf 0 0 0 1 0
Region of residenceg
Northeast 0 1 0 1 2
Midwest 0 0 1 1 2
South 2 3 3 3 3
West 0 1 1 0 2
US dependent areas 0 0 0 0 0
Subtotal 2 5 5 5 9
Additional gender identityh
Age at death (yr)
13–14 0 0 0 0 0
15–19 0 0 0 0 0
20–24 0 0 0 0 0
25–29 0 0 0 0 0
30–34 1 1 0 0 0
35–39 0 0 0 0 0
40–44 0 0 0 1 0
45–49 0 0 0 0 0
50–54 0 0 0 0 0
55–59 0 1 1 0 0
60–64 0 0 0 0 0
≥65 0 0 0 0 0
Race/ethnicity
American Indian/Alaska Native 0 0 0 0 0
Asianb 0 0 0 0 0
Black/African American 1 0 0 1 0
Hispanic/Latinoc 0 1 1 0 0
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 0 1 0 0 0
Multiracial 0 0 0 0 0
Exposure categoryd
     Sexual contacte 1 1 0 1 0
     Injection drug use 0 0 0 0 0
Sexual contacte
and injection drug use
0 1 1 0 0
   Otherf 0 0 0 0 0
Region of residenceg
Northeast 0 1 0 1 0
Midwest 0 1 0 0 0
South 0 0 0 0 0
West 1 0 1 0 0
US dependent areas 0 0 0 0 0
Subtotal 1 2 1 1 0
Total 123 115 124 152 198

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Additional gender identity not included due to small numbers.

a“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
bIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
cHispanic/Latino persons can be of any race.
dClassification of adults and adolescents based on their risk factors that may have been responsible for HIV transmission; classification has no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. The categories are mutually exclusive. Data were not statistically adjusted to account for missing exposure category.
eFor persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
fOther risk factors including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
gData are based on residence at the time of death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
hAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 15a. Persons living with diagnosed HIV infection, by year and selected characteristics, 2016–2020—United States
2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Gender
Male 731,528 750,778 769,364 787,151 798,697
Female 231,679 235,624 239,274 242,869 244,205
Transgender woman/girlb 9,855 10,378 10,918 11,466 11,949
Transgender man/boyb 362 390 437 479 509
Additional gender identityc 166 184 202 226 243
Age at end of year
<13 2,210 4.2 2,057 3.9 1,894 3.6 1,669 3.2 1,444 2.8
13–14 679 8.3 669 8.1 666 8.0 650 7.8 640 7.6
15–19 4,639 21.9 4,536 21.5 4,358 20.7 4,238 20.1 3,778 18.0
20–24 29,783 133.2 28,381 128.6 26,949 123.5 25,982 120.0 24,186 112.0
25–29 68,250 297.5 70,339 301.1 70,809 300.7 69,281 294.3 65,455 281.8
30–34 78,999 361.8 82,684 376.5 87,608 395.8 93,030 414.1 97,029 424.9
35–39 89,346 429.9 91,617 432.3 93,487 433.8 95,411 438.6 96,659 442.8
40–44 97,070 493.3 95,806 489.4 96,455 490.0 97,980 491.9 100,348 494.1
45–49 135,715 649.1 129,676 620.5 123,026 593.9 116,855 573.1 109,234 547.0
50–54 165,941 761.3 162,434 761.5 157,168 753.6 150,353 734.5 145,107 711.5
55–59 135,369 617.0 143,953 656.0 152,372 695.3 159,672 730.1 162,542 752.4
60–64 87,269 448.7 95,802 480.7 103,919 511.8 111,790 543.7 120,013 577.0
≥65 78,320 159.2 89,400 176.1 101,484 193.8 115,280 213.3 129,168 232.1
Race/ethnicity
American Indian/Alaska Native 2,690 112.9 2,848 118.8 2,976 123.5 3,124 129.0 3,248 133.5
Asiand 12,948 72.5 13,908 75.8 14,795 79.0 15,558 81.6 16,198 83.6
Black/African American 396,530 985.3 406,215 1000.8 415,577 1016.1 424,689  1,031.0 430,015      1,038.0
Hispanic/Latinoe 217,205 379.2 225,188 385.6 233,010 391.8 240,872 398.8 246,097 401.4
Native Hawaiian/other Pacific Islander 738 129.5 777 133.4 827 139.3 880 145.7 936 152.6
White 290,404 146.7 294,999 149.1 299,442 151.6 303,443 153.8 305,956 155.5
Multiracial 52,339 768.6 52,685 752.2 52,834 734.6 52,895 717.1 52,423 693.7
Transmission categoryf
     Male sex at birth (≥13 yrs at end of year)g
     Male-to-male sexual contact 531,004 550,084 568,405 586,044 599,433
     Injection drug use 68,935 68,166 67,525 66,954 65,912
 Male-to-male sexual contact
and injection drug use
56,977 57,124 57,180 57,361 56,882
     Heterosexual contacth 76,039 77,339 78,725 79,821 80,035
     Perinatali 4,732 4,832 4,928 5,051 5,135
     Otherj 2,799 2,800 2,791 2,794 2,783
     Subtotal 740,486 560.5 760,344 570.9 779,554 581.3 798,026 591.2 810,180 596.8
     Female sex at birth (≥13 yrs at end of year)g
     Injection drug use 49,201 48,995 48,837 48,727 48,195
     Heterosexual contacth 174,674 178,746 182,501 186,172 188,033
     Perinatali 5,351 5,532 5,713 5,876 6,015
     Otherj 1,668 1,680 1,697 1,722 1,736
     Subtotal 230,894 167.1 234,953 168.8 238,747 170.3 242,496 171.9 243,979 172.0
     Child (<13 yrs at end of year)
     Perinatal 1,827 1,701 1,548 1,372 1,194
     Otherj 383 356 346 297 250
     Subtotal 2,210 4.2 2,057 3.9 1,894 3.6 1,669 3.2 1,444 2.8
Region of residencek
Northeast 230,044 410.3 232,022 413.7 234,097 417.4 235,593 420.7 235,337 421.4
Midwest 115,828 170.3 118,984 174.6 122,094 178.9 124,872 182.7 126,929 185.8
South 436,538 356.6 449,534 363.7 461,779 370.5 474,316 377.4 482,479 380.9
West 191,180 249.7 196,814 254.7 202,225 259.8 207,410 264.9 210,858 268.1
Totall 973,590 301.4 997,354 306.8 1,020,195 312.1 1,042,191 317.4 1,055,603 320.4

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

aRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
b“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
dIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
eHispanic/Latino persons can be of any race.
fTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
gData include transgender and additional gender identity persons.
hSexual contact with a person known to have, or with a risk factor for, HIV infection.
iIncludes individuals aged ≥13 years at time of diagnosis of HIV infection.
jOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
kData are based on address of residence at the end of the specified year (i.e., most recent known address).
lIncludes persons whose race/ethnicity is unknown.

Table 15b. Persons living with diagnosed HIV infection, by year and selected characteristics, 2016–2020—United States and 6 dependent areas
2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Gender
Male 743,223 762,324 780,831 798,709 810,267
Female 236,769 240,574 244,164 247,754 249,044
Transgender woman/girlb 9,890 10,413 10,949 11,499 11,985
Transgender man/boyb 363 391 439 481 512
Additional gender identityc 167 184 203 226 243
Age at end of year
<13 2,224 4.2 2,066 3.9 1,900 3.6 1,674 3.2 1,447 2.8
13–14 682 8.2 675 8.1 674 8.0 654 7.8 643 7.6
15–19 4,686 21.9 4,581 21.4 4,400 20.6 4,264 20.0 3,800 17.9
20–24 30,131 133.1 28,677 128.5 27,216 123.3 26,232 119.8 24,403 111.8
25–29 69,013 297.6 71,045 300.9 71,504 300.6 69,966 294.1 66,068 281.4
30–34 79,964 362.5 83,595 377.0 88,485 396.2 93,936 414.3 97,943 424.8
35–39 90,749 431.7 92,903 433.7 94,664 434.9 96,491 439.3 97,688 443.4
40–44 98,741 495.8 97,393 491.7 97,974 492.2 99,438 493.7 101,775 495.8
45–49 138,131 653.0 131,864 623.8 125,006 596.7 118,722 575.7 110,929 549.3
50–54 168,965 766.2 165,360 766.2 159,981 758.2 152,961 738.6 147,624 715.6
55–59 137,939 621.7 146,606 660.7 155,114 700.0 162,572 735.1 165,411 757.1
60–64 89,003 452.3 97,654 484.4 105,941 516.0 113,927 548.0 122,308 581.5
≥65 80,184 160.7 91,467 177.8 103,727 195.5 117,832 215.2 132,012 234.1
Race/ethnicity
American Indian/Alaska Native 2,692 2,850 2,978 3,126 3,250
Asiand 13,000 13,964 14,856 15,626 16,266
Black/African American 396,835 406,513 415,886 425,003 430,332
Hispanic/Latinoe 233,531 241,218 248,889 256,817 262,007
Native Hawaiian/other Pacific Islander 767 809 858 912 968
White 290,485 295,085 299,526 303,536 306,048
Multiracial 52,363 52,710 52,856 52,916 52,447
Transmission categoryf
     Male sex at birth (≥13 yrs at end of year)g
     Male-to-male sexual contact 535,741 554,845 573,263 591,073 604,590
     Injection drug use 72,548 71,657 70,889 70,228 69,099
Male-to-male sexual contact
and injection drug use
57,809 57,919 57,945 58,120 57,629
     Heterosexual contacth 78,423 79,709 81,079 82,192 82,394
     Perinatali 4,864 4,963 5,058 5,183 5,265
     Otherj 2,826 2,827 2,817 2,820 2,808
     Subtotal 752,210 562.9 771,920 573.1 791,050 583.5 809,615 593.3 821,785 598.9
     Female sex at birth (≥13 yrs at end of year)g
     Injection drug use 50,248 49,985 49,792 49,670 49,114
     Heterosexual contacth 178,573 182,568 186,307 189,994 191,832
     Perinatali 5,477 5,655 5,829 5,984 6,126
     Otherj 1,680 1,692 1,708 1,732 1,747
     Subtotal 235,978 168.7 239,900 170.3 243,636 171.8 247,380 173.3 248,819 173.4
     Child (<13 yrs at end of year)
     Perinatal 1,841 1,710 1,554 1,377 1,197
     Otherj 383 356 346 297 250
     Subtotal 2,224 4.2 2,066 3.9 1,900 3.6 1,674 3.2 1,447 2.8
Region of residencek
Northeast 230,044 410.3 232,022 413.7 234,097 417.4 235,593 420.7 235,337 421.4
Midwest 115,828 170.3 118,984 174.6 122,094 178.9 124,872 182.7 126,929 185.8
South 436,538 356.6 449,534 363.7 461,779 370.5 474,316 377.4 482,479 380.9
West 191,180 249.7 196,814 254.7 202,225 259.8 207,410 264.9 210,858 268.1
U.S. dependent areas 16,822 441.9 16,532 443.9 16,391 456.4 16,478 459.0 16,448 462.7
Totall 990,412 303.0 1,013,886 308.3 1,036,586 313.7 1,058,669 319.0 1,072,051 321.9

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

aRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
b“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
dIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
eHispanic/Latino persons can be of any race.
fTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
gData include transgender and additional gender identity persons.
hSexual contact with a person known to have, or with a risk factor for, HIV infection.
iIncludes individuals aged ≥13 years at time of diagnosis of HIV infection.
jOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
kData are based on address of residence at the end of the specified year (i.e., most recent known address).
lIncludes persons whose race/ethnicity is unknown.

Table 16a. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2020 (COVID-19 Pandemic)—United States
American Indian/Alaska Native Asiana Black/African American Hispanic/Latinob Native Hawaiian/other Pacific Islander White Multiracial Totalc
No. Rated No. Rated No. Rated No. Rated No. Rated No. Rated No. Rated No. Rated
Gender
Male 2,390 13,156 281,564 196,810 750 264,233 39,268 798,697
Female 796 2,830 142,547 45,181 151 40,316 12,180 244,205
Transgender woman/girle 57 197 5,592 3,931 35 1,235 902 11,949
Transgender man/boye 4 9 219 108 0 124 45 509
Additional gender identityf 1 6 93 67 0 48 28 243
Age at end of year 
<13 7 1.7 100 3.5 843 11.8 192 1.4 3 2.6 182 0.7 117 4.6 1,444 2.8
13–14 1 1.4 33 7.8 374 32.4 85 3.9 0 0.0 88 2.1 59 16.8 640 7.6
15–19 11 6.3 96 8.7 2,311 81.0 763 14.9 7 16.7 421 3.9 169 21.8 3,778 18.0
20–24 98 54.0 387 31.3 13,509 444.5 5,835 118.9 26 60.6 3,323 28.9 1,003 144.9 24,186 112.0
25–29 268 135.4 1,185 77.4 33,053 961.4 16,688 336.3 80 160.9 10,895 87.6 3,279 538.9 65,455 281.8
30–34 374 206.0 1,792 106.4 46,183 1460.4 24,545 526.1 122 228.7 18,879 149.6 5,127 1094.9 97,029 424.9
35–39 392 244.3 1,877 115.2 40,805 1461.0 26,543 588.1 118 235.9 21,692 176.4 5,227 1356.2 96,659 442.8
40–44 377 258.8 2,019 137.9 40,593 1559.5 28,166 665.9 130 303.8 23,833 207.3 5,210 1606.7 100,348 494.1
45–49 345 246.0 2,392 168.1 43,155 1711.2 29,123 754.1 99 263.1 28,557 243.9 5,522 1994.0 109,234 547.0
50–54 452 317.0 2,191 176.7 54,228 2151.4 34,943 1031.4 103 288.6 45,675 356.2 7,415 3034.4 145,107 711.5
55–59 401 258.4 1,629 144.7 59,336 2284.4 33,620 1148.7 103 295.8 59,200 407.5 8,092 3444.3 162,542 752.4
60–64 264 182.6 1,115 109.2 46,380 1938.4 22,479 965.1 72 238.9 43,863 299.0 5,684 2696.4 120,013 577.0
≥65 258 81.2 1,382 52.8 49,245 949.8 23,115 473.5 73 113.5 49,348 117.1 5,519 1215.6 129,168 232.1
Transmission categoryg
    Male sex at birth (≥13 yrs at end of year)h
Male-to-male sexual contact 1,740 11,252 187,976 150,900 672 217,022 29,508 599,433
Injection drug use 227 452 30,306 18,742 23 13,429 2,662 65,912
Male-to-male sexual contact
and injection drug use
302 417 15,327 13,224 48 23,153 4,363 56,882
Heterosexual contacti 159 1,068 49,490 16,185 35 9,947 3,122 80,035
    Perinatalj 5 60 2,930 1,223 3 568 338 5,135
    Otherk 13 66 803 437 2 1,307 150 2,783
    Subtotal 2,445 248.8 13,315 171.1 286,831 1772.7 200,711 832.6 783 311.5 265,426 316.0 40,143 1643.1 810,180 596.8
    Female sex at birth (≥13 yrs at end of year)h
Injection drug use 267 188 22,684 9,365 25 12,648 2,953 48,194
Heterosexual contacti 510 2,459 115,289 34,215 123 26,577 8,735 188,033
    Perinatalj 9 63 3,565 1,350 0 633 388 6,015
    Otherk 10 73 803 264 2 490 88 1,736
    Subtotal 796 77.2 2,783 31.9 142,341 787.2 45,194 189.7 150 60.3 40,348 46.2 12,163 471.0 243,979 172.0
    Child (<13 yrs at end of year)
    Perinatal 6 61 697 180 3 141 106 1,194
    Otherk 1 39 146 12 0 41 11 250
    Subtotal 7 1.7 100 3.5 843 11.8 192 1.4 3 2.6 182 0.7 117 4.6 1,444 2.8
Region of residencel
Northeast 144 111.9 3,466 88.8 89,494 1,413.6 73,061 869.9 64 282.6 53,710 149.0 15,055 1,487.6 235,337 421.4
Midwest 397 96.0 1,596 66.0 54,193 751.9 16,018 283.9 50 128.7 48,040 93.9 6,515 450.6 126,929 185.8
South 793 97.0 3,419 72.8 253,184 1,043.7 84,830 361.6 163 161.2 117,902 166.5 22,034 870.4 482,479 380.9
West 1,914 178.5 7,717 92.4 33,144 913.0 72,188 303.2 659 146.1 86,304 222.6 8,819 343.4 210,858 268.1
Total 3,248 133.5 16,198 83.6 430,015 1038.0 246,097 401.4 936 152.6 305,956 155.5 52,423 693.7 1,055,603 320.4

Note: Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

aIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
bHispanic/Latino persons can be of any race.
cIncludes persons whose race/ethnicity is unknown.
dRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
e“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
fAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
gTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
hData include transgender and additional gender identity persons.
iSexual contact with a person known to have, or with a risk factor for, HIV infection.
jIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
kOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
lData are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 16b. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2020 (COVID-19 Pandemic)—United States and 6 dependent areas
American Indian/Alaska Native Asiana Black/African American Hispanic/Latinob Native Hawaiian/other Pacific Islander White Multiracial Totalc
No. No. No. No. No. No. No. No.
Gender
Male 2,392 13,213 281,755 208,010 774 264,307 39,288 810,267
Female 796 2,841 142,673 49,853 158 40,334 12,184 249,044
Transgender woman/girld 57 197 5,592 3,966 36 1,235 902 11,985
Transgender man/boyd 4 9 219 111 0 124 45 512
Additional gender identitye 1 6 93 67 0 48 28 243
Age at end of year
<13 7 100 844 193 4 182 117 1,447
13–14 1 33 374 88 0 88 59 643
15–19 11 96 2,314 781 7 421 170 3,800
20–24 98 387 13,511 6,048 27 3,324 1,003 24,403
25–29 268 1,186 33,059 17,289 83 10,896 3,280 66,068
30–34 374 1,801 46,198 25,421 130 18,884 5,128 97,943
35–39 392 1,882 40,823 27,537 121 21,699 5,229 97,688
40–44 377 2,025 40,614 29,555 134 23,837 5,213 101,775
45–49 345 2,401 43,196 30,755 101 28,563 5,525 110,929
50–54 453 2,202 54,288 37,358 108 45,695 7,420 147,624
55–59 401 1,641 59,374 36,418 104 59,218 8,094 165,411
60–64 265 1,123 46,421 24,704 74 43,878 5,687 122,308
≥65 258 1,389 49,316 25,860 75 49,363 5,522 132,012
Transmission categoryf
     Male sex at birth (≥13 yrs at end of year)g
 Male-to-male sexual contact 1,741 11,299 188,059 155,825 692 217,085 29,524 604,590
     Injection drug use 227 458 30,341 21,884 24 13,432 2,663 69,099
 Male-to-male sexual contact
and injection drug use
302 419 15,333 13,955 50 23,157 4,365 57,629
Heterosexual contacth 160 1,070 49,553 18,471 38 9,951 3,122 82,394
     Perinatali 5 60 2,932 1,350 3 568 338 5,265
     Otherj 13 66 803 462 2 1,307 150 2,808
     Subtotal 2,447 13,372 287,021 211,946 808 265,500 40,163 821,785
     Female sex at birth (≥13 yrs at end of year)g
     Injection drug use 267 190 22,698 10,262 25 12,652 2,953 49,114
 Heterosexual contacth 510 2,468 115,394 37,878 129 26,590 8,738 191,832
     Perinatali 9 63 3,569 1,455 0 634 389 6,126
     Otherj 10 73 806 273 2 490 88 1,747
     Subtotal 796 2,794 142,467 49,868 156 40,366 12,167 248,819
     Child (<13 yrs at end of year)
     Perinatal 6 61 698 181 4 141 106 1,197
     Otherj 1 39 146 12 0 41 11 250
     Subtotal 7 100 844 193 4 182 117 1,447
Region of residencek
Northeast 144 3,466 89,494 73,061 64 53,710 15,055 235,337
Midwest 397 1,596 54,193 16,018 50 48,040 6,515 126,929
South 793 3,419 253,184 84,830 163 117,902 22,034 482,479
West 1,914 7,717 33,144 72,188 659 86,304 8,819 210,858
U.S. dependent areas 2 68 317 15,910 32 92 24 16,448
Total 3,250 16,266 430,332 262,007 968 306,048 52,447 1,072,051

Note: Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

aIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
bHispanic/Latino persons can be of any race.
cIncludes persons whose race/ethnicity is unknown.
d“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender
eAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
fTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
gData include transgender and additional gender identity persons.
hSexual contact with a person known to have, or with a risk factor for, HIV infection.
iIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
jOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
kData are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.

Table 17a. Persons aged ≥13 years living with diagnosed HIV infection, by year, sex assigned at birth, and selected characteristics, 2016–2020—United States
2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Male sex at birthb
Age at end of year
13–14 312 7.5 301 7.1 297 7.0 307 7.2 311 7.2
15–19 2,970 27.5 2,975 27.6 2,874 26.7 2,851 26.5 2,484 23.2
20–24 24,180 210.5 23,116 204.3 22,054 197.4 21,352 192.9 20,028 181.5
25–29 56,654 485.5 58,961 495.6 59,617 496.3 58,592 487.4 55,458 467.0
30–34 62,180 565.4 66,146 596.9 71,411 638.4 76,736 674.9 80,877 699.1
35–39 65,199 627.8 67,959 641.3 70,426 653.2 73,036 670.5 75,411 689.5
40–44 68,340 699.6 67,682 696.4 68,409 699.4 70,302 709.7 72,953 721.7
45–49 100,825 973.6 95,155 919.4 89,532 873.5 84,079 833.9 77,840 788.4
50–54 127,883 1,194.2 124,711 1,189.4 119,807 1,167.4 113,689 1,127.6 108,763    1,082.0
55–59 104,044 975.7 110,687 1037.3 117,372 1,101.2 123,071 1,156.8 125,217    1,191.2
60–64 67,133 722.0 73,524 771.6 79,467 817.8 85,326 866.1 91,643 918.5
≥65 60,766 279.0 69,127 306.9 78,288 336.4 88,685 368.6 99,195 399.6
Race/ethnicity
American Indian/Alaska Native 1,973 208.0 2,100 219.3 2,212 228.9 2,333 239.3 2,445 248.8
Asianc 10,526 147.9 11,352 155.0 12,118 161.7 12,767 167.0 13,315 171.1
Black/African American 260,259 1,670.9 267,629 1,700.2 274,927 1,730.0 282,113 1,758.4 286,831    1,772.7
Hispanic/Latinod 174,395 788.3 181,561 802.0 188,627 814.8 195,755 828.6 200,711 832.6
Native Hawaiian/other Pacific Islander 610 263.4 647 273.1 694 286.8 743 301.0 783 311.5
White 252,420 300.6 256,392 305.0 260,161 309.4 263,410 313.2 265,426 316.0
Multiracial 39,773 1,869.7 40,134 1,820.9 40,286 1,766.1 40,379 1,709.9 40,143    1,643.1
Transmission categorye
   Male-to-male sexual contact 531,004 550,084 568,405 586,044 599,433
   Injection drug use 68,935 68,166 67,525 66,954 65,912
Male-to-male sexual contact
and injection drug use
56,977 57,124 57,180 57,361 56,882
   Heterosexual contactf 76,039 77,339 78,725 79,821 80,035
   Perinatalg 4,732 4,832 4,928 5,051 5,135
   Otherh 2,799 2,800 2,791 2,794 2,783
Region of residencei
Northeast 161,984 702.6 163,829 709.3 165,728 716.6 167,279 723.4 167,483 725.2
Midwest 91,473 328.2 93,963 335.8 96,426 343.6 98,564 350.2 100,260 355.7
South 320,530 646.3 331,048 660.1 341,199 673.8 351,458 687.1 358,705 694.5
West 166,499 527.2 171,504 536.8 176,201 545.9 180,725 554.9 183,732 559.8
Subtotal 740,486 560.5 760,344 570.9 779,554 581.3 798,026 591.2 810,180 596.8
Female sex at birthb
Age at end of year
13–14 367 9.1 368 9.1 369 9.1 343 8.4 329 8.0
15–19 1,669 16.1 1,561 15.1 1,484 14.4 1,387 13.4 1,294 12.6
20–24 5,603 51.5 5,265 49.0 4,895 46.0 4,630 43.8 4,158 39.4
25–29 11,596 102.9 11,378 99.3 11,192 97.0 10,689 92.8 9,997 88.0
30–34 16,819 155.2 16,538 152.0 16,197 148.0 16,294 146.9 16,152 143.3
35–39 24,147 232.2 23,658 223.3 23,061 214.2 22,375 206.0 21,248 195.1
40–44 28,730 289.9 28,124 285.3 28,046 283.3 27,678 276.4 27,395 268.6
45–49 34,890 330.7 34,521 327.3 33,494 320.0 32,776 318.0 31,394 310.9
50–54 38,058 343.3 37,723 347.9 37,361 352.7 36,664 353.0 36,344 351.4
55–59 31,325 277.8 33,266 295.0 35,000 310.9 36,601 325.9 37,325 336.5
60–64 20,136 198.3 22,278 214.2 24,452 231.0 26,464 247.1 28,370 262.1
≥65 17,554 64.0 20,273 71.8 23,196 79.8 26,595 88.7 29,973 97.2
Race/ethnicity
American Indian/Alaska Native 711 71.8 742 74.1 758 75.0 785 76.8 796 77.2
Asianc 2,307 28.8 2,442 29.6 2,567 30.5 2,680 31.2 2,783 31.9
Black/African American 134,933 773.5 137,345 779.6 139,534 784.9 141,598 789.4 142,341 787.2
Hispanic/Latinod 42,516 195.1 43,356 194.3 44,133 193.2 44,896 192.4 45,194 189.7
Native Hawaiian/other Pacific Islander 125 54.5 127 54.1 131 54.6 135 55.2 150 60.3
White 37,708 43.1 38,357 43.9 39,040 44.6 39,824 45.5 40,348 46.2
Multiracial 12,388 545.5 12,379 527.4 12,379 510.8 12,374 494.6 12,163 471.0
Transmission categorye
 Injection drug use 49,201 48,995 48,837 48,727 48,195
 Heterosexual contactf 174,674 178,746 182,501 186,172 188,033
 Perinatalg 5,351 5,532 5,713 5,876 6,015
 Otherh 1,668 1,680 1,697 1,722 1,736
Region of residencei
Northeast 67,698 274.5 67,871 274.9 68,097 275.7 68,067 275.7 67,648 274.5
Midwest 23,871 82.3 24,552 84.4 25,206 86.4 25,908 88.6 26,319 89.9
South 115,016 219.5 117,550 221.8 119,722 223.6 122,102 225.7 123,110 225.3
West 24,309 75.8 24,980 77.0 25,722 78.5 26,419 80.0 26,902 80.8
Subtotal 230,894 167.1 234,953 168.8 238,747 170.3 242,496 171.9 243,979 172.0
Total 971,380 359.4 995,297 365.4 1,018,301 371.3 1,040,522 376.9 1,054,159 379.7

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

aRates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
bData include transgender and additional gender identity persons.
cIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
dHispanic/Latino persons can be of any race.
eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
fSexual contact with a person known to have, or with a risk factor for, HIV infection.
gIncludes individuals aged ≥13 years at time of diagnosis of HIV infection.
hOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
iData are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 17b. Persons aged ≥13 years living with diagnosed HIV infection, by year, sex assigned at birth, and selected characteristics, 2016–2020—United States and 6 dependent areas
2016 2017 2018 2019 2020 (COVID-19 Pandemic)
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Male sex at birthb
Age at end of year
13–14 314 7.4 303 7.1 301 7.0 310 7.2 313 7.2
15–19 2,996 27.4 2,997 27.5 2,901 26.7 2,868 26.4 2,498 23.1
20–24 24,444 210.3 23,344 203.9 22,252 197.0 21,549 192.6 20,206 181.1
25–29 57,254 485.5 59,521 495.1 60,181 496.0 59,149 487.0 55,953 466.4
30–34 62,890 566.3 66,826 597.5 72,081 638.8 77,441 675.0 81,605 699.0
35–39 66,170 630.3 68,860 643.2 71,259 654.7 73,826 671.6 76,190 690.5
40–44 69,468 703.0 68,767 699.6 69,461 702.5 71,326 712.4 73,950 724.1
45–49 102,504 978.6 96,658 923.6 90,855 876.9 85,316 837.0 78,982 791.4
50–54 130,000 1,200.5 126,774 1,195.6 121,818 1,173.9 115,548 1,133.4 110,548    1,087.8
55–59 105,775 981.3 112,500 1043.2 119,269 1,107.3 125,086 1,163.4 127,218    1,197.4
60–64 68,354 727.0 74,827 776.7 80,850 823.1 86,771 871.4 93,188 924.1
≥65 62,041 281.0 70,543 309.1 79,822 338.5 90,425 370.9 101,134 402.2
Race/ethnicity
American Indian/Alaska Native 1,975 2,102 2,214 2,335 2,447
Asianc 10,567 11,397 12,168 12,824 13,372
Black/African American 260,435 267,801 275,110 282,299 287,021
Hispanic/Latinod 185,794 192,804 199,778 206,980 211,946
Native Hawaiian/other Pacific Islander 631 671 719 768 808
White 252,484 256,459 260,227 263,484 265,500
Multiracial 39,792 40,155 40,303 40,397 40,163
Transmission categorye
Male-to-male sexual contact 535,741 554,845 573,263 591,073 604,590
Injection drug use 72,548 71,657 70,888 70,228 69,099
Male-to-male sexual contact
and injection drug use
57,809 57,919 57,945 58,120 57,629
Heterosexual contactf 78,423 79,709 81,079 82,192 82,394
Perinatalg 4,864 4,962 5,058 5,183 5,265
Otherh 2,826 2,827 2,817 2,820 2,808
Region of residencei
Northeast 161,984 702.6 163,829 709.3 165,728 716.6 167,279 723.4 167,483 725.2
Midwest 91,473 328.2 93,963 335.8 96,426 343.6 98,564 350.2 100,260 355.7
South 320,530 646.3 331,048 660.1 341,199 673.8 351,458 687.1 358,705 694.5
West 166,499 527.2 171,504 536.8 176,201 545.9 180,725 554.9 183,732 559.8
U.S. dependent areas 11,724 763.1 11,576 765.3 11,496 781.3 11,589 784.3 11,605 789.2
Subtotal 752,210 562.9 771,920 573.1 791,050 583.5 809,615 593.3 821,785 598.9
Female sex at birthb
Age at end of year
13–14 368 9.0 372 9.1 373 9.1 344 8.3 330 7.9
15–19 1,690 16.1 1,584 15.2 1,499 14.4 1,396 13.4 1,302 12.5
20–24 5,687 51.6 5,333 49.0 4,964 46.1 4,683 43.8 4,197 39.3
25–29 11,759 103.2 11,524 99.4 11,323 97.1 10,817 92.9 10,115 88.1
30–34 17,074 155.9 16,769 152.6 16,404 148.4 16,495 147.3 16,338 143.6
35–39 24,579 233.6 24,043 224.4 23,405 215.1 22,665 206.6 21,498 195.5
40–44 29,273 291.7 28,626 286.9 28,513 284.6 28,112 277.5 27,825 269.8
45–49 35,627 333.6 35,206 329.8 34,151 322.6 33,406 320.3 31,947 312.7
50–54 38,965 347.1 38,586 351.5 38,163 355.9 37,413 355.8 37,076 354.2
55–59 32,164 281.9 34,106 299.0 35,845 314.8 37,486 329.9 38,193 340.3
60–64 20,649 200.9 22,827 216.9 25,091 234.3 27,156 250.7 29,120 266.0
≥65 18,143 65.2 20,924 73.1 23,905 81.1 27,407 90.2 30,878 98.8
Race/ethnicity
American Indian/Alaska Native 711 742 758 785 796
Asianc 2,318 2,453 2,578 2,691 2,794
Black/African American 135,060 137,470 139,659 141,725 142,467
Hispanic/Latinod 47,433 48,136 48,857 49,613 49,868
Native Hawaiian/other Pacific Islander 132 134 136 141 156
White 37,725 38,376 39,058 39,843 40,366
Multiracial 12,392 12,383 12,384 12,377 12,167
Transmission categorye
Injection drug use 50,248 49,985 49,792 49,670 49,114
Heterosexual contactf 178,573 182,568 186,307 189,994 191,832
Perinatalg 5,477 5,655 5,829 5,984 6,126
Otherh 1,680 1,692 1,708 1,732 1,747
Region of residencei
Northeast 67,698 274.5 67,871 274.9 68,097 275.7 68,067 275.7 67,648 274.5
Midwest 23,871 82.3 24,552 84.4 25,206 86.4 25,908 88.6 26,319 89.9
South 115,016 219.5 117,550 221.8 119,722 223.6 122,102 225.7 123,110 225.3
West 24,309 75.8 24,980 77.0 25,722 78.5 26,419 80.0 26,902 80.8
U.S. dependent areas 5,084 297.3 4,947 293.9 4,889 298.8 4,884 296.9 4,840 295.1
Subtotal 235,978 168.7 239,900 170.3 243,636 171.8 247,380 173.3 248,819 173.4
Total 988,188 361.3 1,011,820 367.1 1,034,686 373.0 1,056,995 378.6 1,070,604 381.4

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

aRates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.
bData include transgender and additional gender identity persons.
cIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
dHispanic/Latino persons can be of any race.
eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
fSexual contact with a person known to have, or with a risk factor for, HIV infection.
gIncludes individuals aged ≥13 years at time of diagnosis of HIV infection.
hOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
iData are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 18a. Transgender and additional gender identity persons aged ≥13 years living with diagnosed HIV infection, by year and selected characteristics, 2016–2020—United States
2016 2017 2018 2019 2020
(COVID-19 Pandemic)
No. No. No. No. No.
Transgender womana
Age at end of year 
13–14 0 0 0 0 1
15–19 103 93 68 66 49
20–24 853 798 770 738 710
25–29 1,861 1,904 1,904 1,814 1,718
30–34 1,602 1,816 2,012 2,266 2,494
35–39 1,373 1,466 1,583 1,705 1,784
40–44 1,098 1,125 1,197 1,272 1,410
45–49 1,096 1,091 1,106 1,153 1,145
50–54 905 991 1,034 1,031 1,076
55–59 557 611 693 785 816
60–64 268 307 343 376 446
≥65 137 174 206 258 299
Race/ethnicity
American Indian/Alaska Native 40 42 49 53 57
Asianb 143 162 170 182 197
Black/African American 4,592 4,857 5,118 5,368 5,592
Hispanic/Latinoc 3,183 3,342 3,542 3,756 3,931
Native Hawaiian/other Pacific Islander 24 26 29 33 35
White 1,018 1,078 1,122 1,182 1,235
Multiracial 853 869 886 890 901
Exposure categoryd
Sexual contacte 8,095 8,590 9,103 9,624 10,102
Injection drug use 16 19 23 24 24
Sexual contacte
and injection drug use
1,572 1,583 1,597 1,613 1,595
Perinatalf 22 22 22 21 20
Otherg 148 162 171 182 207
Region of residenceh
Northeast 2,627 2,751 2,898 2,999 3,091
Midwest 1,324 1,403 1,496 1,546 1,624
South 3,521 3,729 3,885 4,095 4,314
West 2,381 2,493 2,637 2,824 2,919
Subtotal 9,853 10,376 10,916 11,464 11,948
Transgender mana
Age at end of year
13–14 1 1 0 0 1
15–19 6 7 7 5 3
20–24 16 19 22 29 39
25–29 44 59 71 74 69
30–34 54 44 61 82 92
35–39 53 64 65 67 75
40–44 42 42 51 54 57
45–49 44 47 50 52 48
50–54 46 47 46 44 47
55–59 28 28 25 34 38
60–64 16 20 26 22 24
≥65 11 11 12 15 16
Race/ethnicity
American Indian/Alaska Native 4 4 4 4 4
Asianb 4 6 8 9 9
Black/African American 166 174 194 211 219
Hispanic/Latinoc 76 81 89 101 108
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 75 86 102 111 124
Multiracial 36 38 39 42 45
Exposure categoryd
   Sexual contacte 257 282 325 359 382
   Injection drug use 5 6 8 9 10
Sexual contacte
and injection drug use
64 63 60 61 62
   Perinatalf 18 18 18 17 19
   Otherg 17 20 25 32 36
Region of residenceh
Northeast 71 74 78 87 91
Midwest 104 109 119 124 125
South 105 117 134 150 173
West 81 89 105 117 120
Subtotal 361 389 436 478 509
Additional gender identityi
Age at end of year
13–14 0 0 0 0 0
15–19 4 2 5 5 2
20–24 13 15 19 24 27
25–29 34 34 34 33 36
30–34 24 27 31 45 53
35–39 15 28 34 38 34
40–44 24 16 15 12 16
45–49 14 23 21 20 25
50–54 12 13 13 18 17
55–59 15 14 15 14 10
60–64 6 7 8 7 12
≥65 5 5 7 10 11
Race/ethnicity
American Indian/Alaska Native 0 0 1 1 1
Asianb 1 2 5 5 6
Black/African American 66 73 78 85 93
Hispanic/Latinoc 47 53 55 63 67
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 31 34 39 44 48
Multiracial 21 22 24 28 28
Exposure categoryd
Sexual contacte 138 156 175 197 211
Injection drug use 1 1 1 1 1
Sexual contacte
and injection drug use
24 23 22 23 24
   Perinatalf 2 2 2 2 2
   Otherg 1 2 2 3 5
Region of residenceh
Northeast 88 107 128 136 139
Midwest 20 22 21 31 38
South 44 40 39 42 43
West 14 15 14 17 23
Subtotal 166 184 202 226 243
Total 10,380 10,949 11,554 12,168 12,700

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

a“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
bIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
cHispanic/Latino persons can be of any race.
dRisk factor data for transgender and additional gender identity adults and adolescents are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
eFor persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
fIndividuals were ≥13 years of age at time of diagnosis of HIV infection.
gOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
hData are based on address of residence at the end of the specified year (i.e., most recent known address).
iAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 18b. Transgender and additional gender identity persons aged ≥13 years living with diagnosed HIV infection, by year and selected characteristics, 2016–2020—United States and 6 dependent areas
2016 2017 2018 2019 2020
(COVID-19 Pandemic)
No. No. No. No. No.
Transgender womana
Age at end of year 
13–14 0 0 0 0 1
15–19 103 93 68 66 49
20–24 856 801 774 743 715
25–29 1,866 1,907 1,906 1,816 1,719
30–34 1,607 1,824 2,019 2,272 2,500
35–39 1,379 1,471 1,586 1,707 1,789
40–44 1,100 1,127 1,202 1,278 1,417
45–49 1,098 1,093 1,106 1,154 1,147
50–54 910 994 1,035 1,034 1,077
55–59 561 617 699 790 821
60–64 269 308 344 378 449
≥65 139 176 208 259 300
Race/ethnicity
American Indian/Alaska Native 40 42 49 53 57
Asianb 143 162 170 182 197
Black/African American 4,592 4,857 5,118 5,368 5,592
Hispanic/Latinoc 3,218 3,377 3,573 3,788 3,966
Native Hawaiian/other Pacific Islander 24 26 29 34 36
White 1,018 1,078 1,122 1,182 1,235
Multiracial 853 869 886 890 901
Exposure categoryd
   Sexual contacte 8,123 8,618 9,128 9,652 10,133
   Injection drug use 16 19 23 24 24
Sexual contacte
and injection drug use
1,579 1,590 1,603 1,618 1,600
   Perinatalf 22 22 22 21 20
   Otherg 148 162 171 182 207
Region of residenceh
Northeast 2,627 2,751 2,898 2,999 3,091
Midwest 1,324 1,403 1,496 1,546 1,624
South 3,521 3,729 3,885 4,095 4,314
West 2,381 2,493 2,637 2,824 2,919
US dependent areas 35 35 31 33 36
Subtotal 9,888 10,411 10,947 11,497 11,984
Transgender mana
Age at end of year
13–14 1 1 0 0 1
15–19 7 8 8 5 3
20–24 16 19 22 30 40
25–29 44 59 71 74 69
30–34 54 44 61 82 92
35–39 53 64 65 67 75
40–44 42 42 52 55 58
45–49 44 47 50 52 48
50–54 46 47 46 44 47
55–59 28 28 25 34 38
60–64 16 20 26 22 24
≥65 11 11 12 15 17
Race/ethnicity
American Indian/Alaska Native 4 4 4 4 4
Asianb 4 6 8 9 9
Black/African American 166 174 194 211 219
Hispanic/Latinoc 77 82 91 103 111
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 75 86 102 111 124
Multiracial 36 38 39 42 45
Exposure categoryd
   Sexual contacte 257 282 326 360 383
   Injection drug use 5 6 8 9 10
Sexual contacte
and injection drug use
64 63 60 61 63
   Perinatalf 19 19 19 18 20
   Otherg 17 20 25 32 36
Region of residenceh
Northeast 71 74 78 87 91
Midwest 104 109 119 124 125
South 105 117 134 150 173
West 81 89 105 117 120
US dependent areas 1 1 2 2 3
Subtotal 362 390 438 480 512
Additional gender identitye
Age at end of year
13–14 0 0 0 0 0
15–19 4 2 5 5 2
20–24 13 15 19 24 27
25–29 34 34 34 33 36
30–34 25 27 32 45 53
35–39 15 28 34 38 34
40–44 24 16 15 12 16
45–49 14 23 21 20 25
50–54 12 13 13 18 17
55–59 15 14 15 14 10
60–64 6 7 8 7 12
≥65 5 5 7 10 11
Race/ethnicity
American Indian/Alaska Native 0 0 1 1 1
Asianb 1 2 5 5 6
Black/African American 66 73 78 85 93
Hispanic/Latinoc 48 53 56 63 67
Native Hawaiian/other Pacific Islander 0 0 0 0 0
White 31 34 39 44 48
Multiracial 21 22 24 28 28
Exposure categoryd
Sexual contacte 139 156 176 197 211
Injection drug use 1 1 1 1 1
Sexual contacte
and injection drug use
24 23 22 23 24
Perinatalf 2 2 2 2 2
Otherg 1 2 2 3 5
Region of residenceh
Northeast 88 107 128 136 139
Midwest 20 22 21 31 38
South 44 40 39 42 43
West 14 15 14 17 23
US dependent areas 1 0 1 0 0
Subtotal 167 184 203 226 243
Total 10,417 10,985 11,588 12,203 12,739

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

a“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
bIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
cHispanic/Latino persons can be of any race.
dRisk factor data for transgender and additional gender identity adults and adolescents are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
eFor persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
fIndividuals were ≥13 years of age at time of diagnosis of HIV infection.
gOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
hData are based on address of residence at the end of the specified year (i.e., most recent known address).
iAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 19a. Persons aged 13–24 years living with diagnosed HIV infection, by age at end of year and sex assigned at birth, and selected characteristics, year-end 2020 (COVID-19 Pandemic)—United States
13–14 years 15–17 years 18–19 years 20–22 years 23–24 years Total
No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea No. Ratea
Sex at birth
Male 311 7.2 706 11.0 1,778 41.3 8,867 134.3 11,161 252.0 22,823 87.7
Female 329 8.0 637 10.4 657 15.9 1,951 30.9 2,207 52.0 5,781 23.2
Race/Ethnicity
American Indian/Alaska Native 1 1.4 1 1.0 10 14.2 47 42.9 51 71.0 110 25.7
Asianb 33 7.8 53 8.1 43 9.5 171 24.1 216 40.9 516 18.6
Black/African American 374 32.4 836 49.5 1,475 126.3 6,268 344.0 7,241 594.9 16,194 229.8
Hispanic/Latinoc 85 3.9 226 7.3 537 26.6 2,523 84.9 3,312 171.2 6,683 54.9
Native Hawaiian/Other Pacific Islander 0 0.0 2 7.9 5 30.4 11 43.2 15 86.0 33 32.4
White 88 2.1 164 2.5 257 5.8 1,351 19.7 1,972 42.5 3,832 14.4
Multiracial 59 16.8 61 12.7 108 36.5 445 104.1 558 210.6 1,231 67.7
Transmission Categoryd
    Male sex at birthe
Male-to-male sexual contact 5 238 1,341 7,743